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ABSTRACT 
 
Che-Pei Kung: The Epstein-Barr Virus Latent Membrane Protein 1 Regulates Gene 
Expression by Engaging Multiple Signaling Pathways 
(Under the direction of Nancy Raab-Traub) 
 
        Epstein-Barr virus (EBV) is a ubiquitous human gammaherpesvirus that is associated 
with a variety of human malignancies of lymphoid and epithelial origins, such as post-
transplant lymphoproliferative disorder (PTLD), Burkitt’s lymphoma (BL), Hodgkin disease 
(HL), nasopharyngeal carcinoma, and others.  Latent membrane protein 1 (LMP1), which is 
expressed in latency type II and III, is considered the EBV oncoprotein due to its ability to 
transform rodent fibroblasts and its critical roles in EBV-mediated B cell transformation.  
Two major signaling domains of LMP1, carboxyl-terminal activating region (CTAR) 1 and 2, 
are responsible for the majority of LMP1-mediated signaling pathways.  However, CTAR1 
and CTAR2 induce distinctive signal transductions and only CTAR1 is essential for LMP1-
mediated cell transformation.  CTAR1 recruits TNFR-associated factors (TRAFs) to induce 
signaling pathways including PI3K/Akt, MEK/ERK, and complex NF-κB signaling.  CTAR1 
is also responsible for LMP1-regulated expression of cellular genes, such as epidermal 
growth factor receptor (EGFR). 
        In this study, multiple signaling pathways engaged by LMP1 through CTAR1 to mediate 
EGFR upregulation were evaluated.  LMP1 has been shown to induce EGFR expression by 
activating transcriptional active complex p50-homodimer/Bcl-3.  This study shows CTAR1 
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also induces the expression of Bcl-3 through activating transcriptional regulator of Bcl-3, 
STAT3, and the STAT3 activation is required for CTAR1’s complete activity to induce EGFR 
expression.  Using mouse embryonic fibroblasts (MEF) defective for different NF-κB 
effectors and TRAFs, we identified that CTAR1-mediated EGFR upregulation is dependent 
on NIK but not canonical or noncanonical NF-κB pathways.  However NIK alone is not 
sufficient to induce EGFR expression, indicating that additional pathways are also needed.  
Consistent with previous studies, TRAF2 and TRAF3 but not TRAF6 are required for 
CTAR1-mediated EGFR induction.  TRAF2 potentially contributes to EGFR induction by 
regulating p50 activation, and this activation is not mediated through the canonical or 
noncanonical NF-κB pathways. 
        Both EGFR and STAT3 are activated by CTAR1 in a serum-independent manner, 
however, the CTAR1-activated EGFR can also activate STAT3 in response to EGF treatment 
and induce the expression of STAT3 target genes.  CTAR1 was found to activate STAT3 
through PKCδ, as inhibition of PKCδ by a chemical inhibitor reduced CTAR1-induced serine 
phosphorylation of STAT3 and Bcl-3 expression.  These findings indicate that CTAR1 
manipulates STAT3 signaling through multiple mechanisms.  PKCδ was also shown to 
mediate CTAR1-induced ERK activation, and inhibition of PKCδ block CTAR1-mediated 
transformation of rodent fibroblast cells.  These results suggest that CTAR1 induce EGFR 
expression by engaging multiple downstream signaling pathways that contribute to LMP1-
mediated gene regulation. 
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Epstein-Barr Virus 
A novel extranodal lymphoma occurring in children was identified in the 1940s by 
Denis Burkitt in equatorial Africa where malaria was endemic (33-35, 54).  Denis Burkitt 
referred to this disease as “African Lymphoma” (currently called Burkitt’s lymphoma) and 
postulated that there may be an infectious agent involved due to the atypical epidemiological 
and clinical features of the disease.  Epstein-Barr virus was discovered in 1964 by Anthony 
Epstein, Yvonne Barr, and Bert Achong in electron micrographs of the cells cultured from 
the tumor specimens provided by Denis Burkitt.  They revealed a herpesvirus-like particle 
that did not react to antibodies from other known herpesviruses and did not replicate in 
cultured cells (79).   
EBV, originally known as human herpesvirus 4 (HHV4), is a prototype member of 
the gamma herpesvirus subfamily and belongs to the lymphocryptovirus (LCV; gamma 1) 
genus (190).  EBV is an enveloped virus with a linear double-stranded DNA genome of more 
than 180 kilobase pairs in length (17, 59, 310, 313).  EBV and most LCVs share four 
characteristic features to their genomes: Single overall format and gene rearrangement, 
Tandem and reiterated direct repeats at both termini (TR), six to twelve tandem and reiterated 
direct internal repeats (IR1), as well as short and long unique sequence domains (US and UL) 
that contain the most of the viral coding capacity (46, 47, 107, 108). 
Gamma herpesviruses are lymphotropic, generally replicate in B or T cells, and have 
a relatively limited range of hosts.  Similarly, EBV can infect B lymphocytes to establish 
lifetime persistence while retain the ability to undergo productive replication in its only 
natural host, humans (190).  EBV is a ubiquitous infectious agent that more than 90% of the 
world adult population is infected with EBV (190).  EBV infection during the childhood is 
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normally asymptomatic and does not cause diseases.  However, delayed infection in 
adolescence may cause infectious mononucleosis (IM) and in individuals like 
immunocompromised patients EBV infection is associated with pathological conditions, 
including the development of cancer (190).  One defining biological property of EBV is its 
ability to transform resting B cells in vitro into lymphoblastoid cell lines (LCLs) (190).  EBV 
is also capable of infecting epithelial cells in vitro and in vivo and is associated with cancers 
of epithelial origins (190, 212, 358).  It has also been reported that EBV can infect cell types 
other than B cells and epithelial cells, such as T cells, natural killer (NK) cells, monocytes, 
and neutrophils (116, 155, 337). 
 
The Life Cycle of EBV 
A schematic illustration of the EBV life cycle is shown in Figure 1.  EBV is normally 
transmitted through saliva that contains both cell-free virus and EBV-infected cells that 
eventually lead to the infection of oral epithelial cells (321).  The mechanism by which EBV 
infects the oral epithelium is still not well understood, although one early study suggested 
that EBV infection begins with the fusion of EBV-infected B cells to epithelial targets (21).  
This model is supported by the observation that infection of epithelial cells is more efficient 
when in close proximity with EBV-producing B cells than with cell-free virus (153, 391).  
Infection of the oral epithelium leads to production of progeny virions through lytic 
replication (204, 205, 357).  Oral epithelium-released virions infect naïve B cells circulating 
near the oral epithelium or in lymphoid organs (255, 278).  Interestingly, EBV infects naïve 
and memory B cells at similar efficiency in vitro (429). 
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EBV infects B cells through the binding of gp350/220 to cell-surface receptor CD21 
to initiate endocytosis into the host cells, as well as the binding of gp42 to class II human 
leukocyte antigen (HLA, also called major histocompatibility complex or MHC) as a co-
receptor (87, 211, 274, 372).  Attachment of EBV to B cells leads to viral fusion with the 
endosomal membrane at a low pH (249).  However, whether CD21 plays a role in EBV 
infection of epithelial cells remains to be determined, indicating that different mechanisms 
may be required for EBV binding and entry of epithelial cells.  It has been shown that EBV 
needs gH and gL to bind to several epithelial cell lines, but the participating receptors have 
not yet been identified (256, 284).  Recently it has been reported that EBV glycoprotein 
BMRF2 interacts with integrin α5β1 and the binding can be blocked by antibodies against 
integrin or BMRF2 (391).  Moreover, endocytosis is not required in EBV infection of 
epithelial cells, and fusion occurs at neutral pH (249).  Interestingly, cell tropism of EBV 
infection can be modified depending on the cell types in which the virus is produced.  
Virions that are made in HLA-class-II-positive B cells are depleted of gp42, and therefore 
target HLA-class-II-negative epithelial cells more effectively than B cells.  Conversely, 
virions produced in epithelial cells can infect B cells more effectively (391). 
Once viral entry is complete, the EBV genome circularizes to form a viral episome in 
the B cells and initiates a limited latency program through transcription from the viral Wp 
promoter using cellular RNA polymerase II (150, 336).  Activation of Wp promoter in 
resting naïve B cells leads to expression of EBNA2, which then turn on a “growth program” 
(similar to type III latency described below) which activates the Cp promoter to initiate B 
cell proliferation (377, 415).  These B cells can undergo germinal center (GC) differentiation 
and become memory B cells (377).  Lifetime viral persistency is established and most viral 
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Figure 1. EBV Life Cycle.  EBV infects the oral epithelium through saliva contact.  Lytic
infection in the oral epithelium leads to amplification of progeny EBVs, which then infect naïve 
B cells in the surrounding lymphoid t issues and drive their proliferation and growth.  The 
infected B cells then undergo germinal center differentiation to become memory B cells.  Most 
viral protein expression is turned off at this point, except for dividing memory B cells, which 
express EBNA1.  Persistently-infected memory B cells occasionally undergo d ifferentiation to 
become plasma cells, where viral reactivation takes place.  Released virus may re-infect other B 
cells or be shed into saliva for spread to other hosts. (Adapted from (379)) 
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proteins are not expressed (375).  Persistently infected memory B cells occasionally undergo 
plasma-cell differentiation which triggers viral reactivation (14, 24, 201, 365).  The newly 
released virus can be shed into saliva for spread to other hosts or for infection of surrounding 
B cells and epithelial cells.   
 
Reverse Genetics with EBV study 
Studies with genetic manipulations of EBV have been hindered due to the limited 
host range of EBV and the lack of permissiveness for EBV replication in most cell lines.  
Several approaches have been tried to conduct reverse genetic studies of EBV.  By 
transfecting latently infected lymphocytes with mutated EBV DNA fragments cloned in 
Escherichia coli, recombinant EBV can be made following lytic program induction and 
homologous recombination (244, 402).  Alternatively, a latently infected cell line with 
replication-competent EBV strain, P3HR1, has been used as the parental strain for 
homologous recombination following transfection of mutated EBV DNA fragments (383).  A 
system using bacterial artificial chromosome (BAC) to produce recombinant EBV has also 
been developed to aid the genetic studies of EBV (63, 171). 
 
Lytic Replication 
Due to the availability of cell lines latently infected with EBV and the lack of good 
genetic tools for EBV primary infection, EBV lytic replication is normally studied by 
inducing the reactivation of EBV in latently infected cells.  Since infection of epithelial cells 
in vitro does not achieve full lytic replication, transformed B cells remains the dominant 
model of infection (429).  In vitro studies have focused on using phorbol esters (TPA) to 
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induce lytic replication through activating protein kinase c (PKC) pathway, which induces 
transcription of EBV immediate early genes including BZLF1 (10, 91).  The lytic program 
can also be induced by activating the B cell receptors using soluble immunoglobulin (371).  
Induction of lytic replication results in the production of infectious virus following cytopathic 
effects on infected cells, such as marginization of heterochromatin, inhibition of host 
macromolecule synthesis, assembly of nucleocapsids, and envelopment of virions through 
the inner nuclear membrane (104, 179, 190, 337).  Like other herpesviruses, EBV lytic 
replication follows a temporal and sequential order and production of lytic genes can be 
divided into three categories, immediate early (IE), early, and late gene expressions (371). 
 
Immediate Early Genes 
BZLF1 (also called Zta or ZEBRA) and BRLF1 (also called Rta) are EBV immediate 
early genes because of their expression in the presence of protein synthesis inhibitors, such as 
cycloheximide.  BZLF1 and BRLF1 are located in the cell nucleus and function as 
transcriptional regulators to initiate and promote lytic infection (113, 122, 315, 362, 371).  
BRLF1 and BZLF1 have both been shown to transactivate early gene promoters and also to 
be required for efficient viral DNA replication (31, 48, 89, 92, 122, 142, 185, 339).  
Moreover, expression of either BZLF1 or BRLF1 during latency will result in the induction 
of the other to drive the virus into the lytic cycle (92, 223, 315).  Uniquely, BZLF1 
preferentially binds to methylated-forms of promoters of BRLF1 and other viral genes (25, 
67).  During the transition from latent to lytic cycle, BZLF1 also ensures the successful 
switch by inhibiting the activity of Cp promoter which regulates the expression of latency-
associated EBNA genes (186).   
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Interaction between BZLF1 and the NF-κB subunit, p65, has been identified and it’s 
believed that they mutually inhibit each other’s transcriptional activity depending on the 
stages of EBV infection (117, 262).  Furthermore, BZLF1 prevents an EBV-stimulated 
immune response by downregulating CIITA, tumor necrosis factor receptor 1 (TNFR1), and 
interferon gamma receptor.  BZLF1 also promotes B-cell proliferation by inducing IL-13 
(209, 263, 264, 387).  Interestingly, it has been recently reported that in AIDS-associated 
primary effusion lymphoma (PEL) co-infected with Kaposi’s sarcoma-associated herpesvirus 
(KSHV) and EBV, lytic replication initiators for both viruses, K-RTA (KSHV) and BZLF1 
(EBV), inhibits each other’s transcriptional activity (165).  This mutual inhibition may be 
important for maintaining viral latency in dually infected cells.    
Recently it has been shown that BRLF1 induces the expression of decoy receptor 3 
(DcR3), which is also upregulated by EBV LMP1 (140, 141).  The upregulation of DcR3 
may contribute to evade immune surveillance and promote cell migration and invasion. 
    
Early Genes 
The expression of EBV early genes is dependent on active protein synthesis but not 
on viral replication.  EBV-encoded early genes are involved with several early events during 
EBV infection, including viral gene transcription and DNA replication (90).  For example, 
EBV DNA polymerase BALF5 is responsible for EBV genome replication during the lytic 
cycle and its activity is dependent on another early gene, BMRF1, which encodes the DNA 
polymerase processivity factor (142, 218).  Another EBV early gene, BHRF1, has been 
identified as a viral homolog of cellular Bcl-2 both sequence-wise and functionally (125).  
Cellular Bcl-2 protects cells from programmed cell death and activation of Bcl-2 by 
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chromosomal translocation is characteristic of human follicular lymphomas (389, 390).  
Therefore, it has been suggested that BHRF1 may function similarly to protect EBV-infected 
cells from apoptosis during the viral life cycle.  Notably, BHRF1 has been recently shown to 
be also expressed in EBV-transformed B cells and BHRF1 may contribute to B cell 
transformation by providing resistance to apoptosis (182).  Interestingly, another EBV early 
gene detected in lytic cycle, BARF1, is also expressed during type II EBV latency (NPC and 
GC) and has been shown to possess tumorigenic potentials (62, 350, 441). 
 
Late Genes 
The last subset of genes expressed during the lytic cycle after viral DNA synthesis, 
usually referred to as late genes, encode viral structural components including tegument 
proteins and glycoproteins (236, 376).  EBV late genes BLLF1 and BZLF2 encoded EBV 
glycoproteins gp350/220 and gp42, respectively (87, 211).  Both gp350/220 and gp42 are 
important for viral entry of EBV into B cells as described previously.  Due to its critical role 
in EBV infection, gp350 has served as a prime candidate for the development of EBV 
vaccines (225, 360).  BCRF1 encodes a viral homolog of IL-10 and it has been shown that 
BCRF1 negatively regulates the host immune response, similar to cellular IL-10, by 
inhibiting activities of T cells, NK cell, and macrophage function (146, 257, 334, 367). 
 
Establishment of Latency 
Types of EBV latency are defined by the expression of specific subsets of EBV latent 
genes, including six EBV-encoded nuclear antigens (EBNAs 1, 2, 3A, 3B, 3C, and LP), three 
latent membrane proteins (LMPs 1, 2A, and 2B), small non-polyadenylated RNAs (EBER1 
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and EBER2), and a group of spliced 3’ transcripts known as BamHIA rightward transcripts 
or BARTs (190, 429).  Genes expressed in certain types of latency, as well as associated 
diseases, are summarized in Table 1.  In type I latency of EBV infection, with Burkitt’s 
lymphoma as the classical example, only EBNA1 is expressed at the protein level along with 
transcripts for the BARTs and EBERs.  Type 0 latency is referred to the cell state where 
infected resting memory B cells do not express EBNA1 before cells undergo cell-division.  
During type II latency, major EBV oncoproteins like LMP1, LMP2A, and LMP2B are 
expressed in addition to EBNA1 as well as the transcripts of BARTs and EBERs.  Type II 
latency is normally seen in EBV-associated Hodgkin disease and EBV-associated diseases of 
epithelial origins, such as nasopharyngeal carcinoma and gastric carcinoma.  In type III 
latency, expression of most EBV latent genes can be detected, including all EBNAs, LMPs, 
EBERs, as well as of BARTs.  Typical examples of type III latency include EBV-generated 
LCLs in vitro and post-transplant lymphoproliferative disorders (PTLDs) (30). 
  
 
LMP1 
EBV latent membrane protein 1 (LMP1) is expressed in latency type II and III.  
LMP1 is the EBV major oncogene since it is essential for EBV-mediated B-cell 
transformation and LMP1 alone can transform rodent fibroblasts in vitro (180, 401).  LMP1 
Latency Type EBV Genes Expressed Associated Malignancies 
Type I EBNA1, BARTs, EBERs Burkitt’s Lymphoma 
Type II 
EBNA1, BARTs, EBERs, 
LMP1, LMP2A and 2B, +/- 
BARF1 
Hodgkin Disease, 
Nasopharyngeal Carcinoma, 
Gastric Carcinoma 
Type III 
EBNA1, 2, 3A, 3B, 3C, and 
LP, BARTs, EBERs, LMP1, 
LMP2A and 2B. 
Lymphoblastoid Cell Lines, 
Post-transplant 
Lymphoproliferative Disorder 
Table 1.  Gene Expression pattern of different types of EBV latency and EBV-
related malignancies associated with each latency type.  
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expression in epithelial cells can significantly affect cell growth, morphological 
transformation, and inhibit cell differentiation (60, 82).  Moreover, LMP1 expression in 
mouse models can cause hyperplasia and B cell lymphomas (197, 414).  LMP1 is an integral 
membrane protein which has 386 amino acids and encodes a 63kDa protein product.  LMP1 
can be basically divided into three domains: first, the N-terminal cytoplasmic tail (aa 1-23), 
which is responsible for the orientation of LMP1; Second, six transmembrane domains (aa 
24-186), which are involved in self aggregation and oligomerization; third, the long C-
terminal cytoplasmic tail (aa 187-386), which is responsible to mediate most of LMP1’s 
signaling activities (429).   
In latently infected B cells, LMP1 mRNA is more abundant than EBNA mRNAs 
despite being regulated by a weak promoter (85).  Transcription of LMP1 is regulated 
through multiple TATA-less sites in the first terminal repeat (TR) to result in a transcript 
with a long 5’ untranslated region (105, 330).  The half-life of LMP1 is less than two hours 
and post-translational modifications of LMP1 include phosphorylation of multiple serine and 
threonine, but not tyrosine, residues (18, 242, 258).  It has been shown that LMP1 associates 
with cytoplasmic cytoskeleton and also incorporates in cholesterol-rich lipid rafts on the cell 
membrane (131, 215, 245).  Although most studies of LMP1 focus on its function in the 
plasma membrane, only half of the cellular LMP1 is found in the plasma membrane, 
indicating that LMP1’s function may be regulated by its cellular localization (216, 241).  
Interestingly, a variety of LMP1 sequence variants have been identified and it seems they 
arise from the onset of primary infection.  These sequence variants appear to associate with 
compartmentalization  (e.g. oral cavity, peripheral blood, or NPC tumors) and could 
potentially provide cell growth advantages (72, 73, 252, 354, 355). 
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LMP1 functions as a constitutively active tumor necrosis factor receptor (TNFR) by 
associating with tumor necrosis factor receptors-associated factors (TRAFs) (160, 250, 265).  
LMP1 is functionally similar to another TNFR member, CD40, and can partially substitute 
for CD40 in B cells (392).  A myriad of signaling pathways have been shown to be activated 
by LMP1, including mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase 
(JNK), phosphatidylinositol 3-kinase (PI3K)-Akt, and NF-κB pathways (77, 239, 290, 320).  
In order to control cell cycle progression, cell proliferation, and migration, LMP1 regulates 
transcriptional expression of many cellular genes, including EGFR, Bcl-2, A20, inhibitor of 
differentiation (Id) 1 and 3, p27, and plakoglobin, (81, 93, 126, 251, 345).  LMP1 has two 
major signaling domains in its c-terminal tail, carboxyl-terminal activating regions 1 and 2 
(CTAR1 and CTAR2), which mediate LMP1-associated signaling pathways through 
recruiting different set of TRAFs.  CTAR1 recruits TRAF1/2/3/5 through a TRAF-binding 
PxQxT motif at aa 204-208 (PQQAT), whereas CTAR2 recruits TRAF2 and TRAF6 through 
TNFR-associated death domain (TRADD), the receptor interacting protein (RIP), and BS69 
(159, 361). 
CTAR1 and CTAR2 have different effects on LMP1-mediated signaling and cellular 
transformation, possibly due to their distinctive TRAF binding patterns.  CTAR1 induces 
MAPK, PI3K/Akt/GSK3β signaling, while CTAR2 activates JNK pathway (76, 239, 240).  
CTAR2 can strongly activate canonical NF-κB signals, while CTAR1 weakly induces NF-κB 
signalings including canonical, noncanonical, and atypical pathways (232, 250).  
Interestingly, it has been reported that expression of LMP1 can be regulated by NF-κB (65, 
168).  Furthermore, CTAR1 is essential for LMP1-mediated transformation of B-lymphocyte 
and rodent fibroblast, while CTAR2 is dispensable (160, 239).  CTAR1 also has unique 
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Figure 2. LMP1-associated signaling pathways.  CTAR1 associates with TRAF1, 2, 3, a nd 5 
and activates a variety of signaling pathways, including PI3K/Akt/GSK3β, MAPKK/ERK, and 
NF-κB pathways.  CTAR1 also regulates expression of proteins involved with proliferation and 
cell cycle regulation, including Id1/Id3, p27, Rb, and EGFR among others.  C TAR2 recruits 
TRAF2 and 6 through TRADD and BS69, followed by activation of JNK and canonical NF-κB 
pathway.  Full-length LMP1 is required for the inhibition of plakoglobin, as well as the initiation 
of the cadherin switch.
Plakoglobin
Id1, Id3
Akt
p27
Rb
CDK2
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effects on regulating cellular gene expression in induction of EGFR, TRAF1, EBI3, Id1, and 
Id3, as well as the repression of p27 (66, 81, 250). 
It has been reported that LMP1 downregulates E-cadherin gene expression via 
activation of DNA methyltransferases to induce cell migration (386).  More recent studies 
revealed that in addition to downregulation of E-cadherin, LMP1 contributes to cell 
migration and NPC metastasis by downregulating junctional protein plakoglobin and 
initiating a “cadherin switch” in LMP1-expressing epithelial cells (345, 346).  A schematic 
illustration of the LMP1-associated signaling pathways is shown in Figure 2. 
 
LMP2A and LMP2B  
LMP2A and LMP2B are two EBV integral membrane proteins.  LMP2A and LMP2B 
share similar structural features, with 12 transmembrane domains and a 27-amino-acid 
cytoplasmic C-terminus (429).  LMP2A has an extra 119-amino-acid cytoplasmic N-
terminus that contains an immunoreceptor-tyrosine activation motif (ITAM) and a 
phosphotyrosine (PY) motif.  The LMP2s are expressed in type II and type III latency, 
however they are not required for EBV-mediated B-cell transformation (226, 227).  LMP2-
mutant EBV-infected cells undergo normal lytic replication upon viral reactivation (192, 
228).  B-cell-targeted expression of LMP2A in transgenic mice can abrogate normal B-cell 
development by mimicking the signaling mediated by B-cell receptor (BCR), resulting in 
colonization of Ig-negative cells in peripheral lymphoid organs (39).  LMP2A can also 
transform epithelial cells and induce cell adhesion and migration, as well as inhibit cell 
differentiation (340).  These results suggest that LMP2A potentially contribute to EBV-
associated tumorigenesis.  The function of LMP2B is not well understood, but recent studies 
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have suggested that LMP2B negatively regulates the function of LMP2A, one of which is to 
prevent the switch from latent to lytic EBV replication (317, 326). 
LMP2A blocks BCR signaling by sequestering the Src family of tyrosine kinases and 
the Syk tyrosine kinase through activated ITAM motif, in which Tyr74 and Tyr85 are 
phosphorylated (32, 94).  Lyn tyrosine kinase can be recruited to a membrane-proximal 
tyrosine residue Tyr112 and mediate phosphorylation of other tyrosine residues of LMP2A 
(95).  Interestingly, LMP2A can be phosphorylated by Csk in epithelial cells instead of Src 
kinase (341).  LMP2A also recruits NEDD4-like ubiquitin protein ligases, such as AIP4, 
WWP2, and Nedd4, through the PY motif to promote the degradation of Lyn and LMP2A, 
providing another mechanism for regulation of BCR signaling (151).  LMP2A also 
contributes to cell transformation by actively activating several signaling pathways, including 
PI3K/Akt/GSK3β, MAPKK/ERK/JUN, and Wnt/β-catenin pathways (45, 260, 261, 340).   
LMP2A has been found to induce expression of a variety of genes that are involved 
with cell cycle progression, inhibition of apoptosis, and evasion of immune response, 
indicating LMP2A’s role in EBV-associated tumorigenesis through transcriptional regulation 
(429).  Interestingly, the transcriptional profiles of LMP2A-expressing B cells or LMP2A 
transgenic mice have been reported to resemble those observed in malignant Hodgkin and 
Reed Sternberg (HRS) cells of Hodgkin disease or germinal center B cells, indicating the 
roles of LMP2A in vivo (307, 308).  A recent study has shown that LMP2A can also cause 
epigenetic abnormality in gastric carcinoma cell line by inducing STAT3-dependent DNA 
methyltransferase 1 (DNMT1) upregulation to decrease transcription of PTEN through 
promoter methylation (135). 
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EBNA1 
EBV-encoded nuclear antigen 1 (EBNA1) is expressed in all types of EBV latency.  
The two main functions of EBNA1 are to maintain the episomal EBV genome and to 
regulate transcription of viral genes.  Through binding to the plasmid origin of viral 
replication, OriP, EBNA1 tethers the viral episome to chromosomes in dividing cells to 
ensure that every daughter cell retains the viral episome after mitosis (285, 424, 425).  Recent 
studies have suggested that EBNA1 binds to OriP through RNA-dependent mechanisms 
(282, 283).  EBNA1 contributes to transcriptional regulation by binding to the promoters 
controlling viral latent genes, including EBNAs and LMP1, in a zinc-dependent manner (6, 
11, 97).  An internal Gly-Ala repeat sequence between the amino- and carboxyl-terminus of 
EBNA1 stabilizes EBNA1 by preventing its proteasome-mediated degradation (206, 207).  
This block of proteasome-mediated degradation and processing of EBNA1 may also 
contribute to the lack of immune response elicited by EBNA1 expression in EBV-infected 
cells (385).  The oncogenic potential of EBNA1 is still under debate.  Although it has been 
shown that EBNA1 is not essential for EBV to establish LCLs, EBNA1 does seem to provide 
certain survival signals to EBV-associated Burkitt’s lymphomas (149, 183).  Moreover, 
EBNA1’s ability to cause cancer in transgenic mouse models has been inconsistent, with 
various results observed among mice with different genetic backgrounds (174, 175, 413). 
 
EBNA2 
Expressed in type III latency, EBNA2 is considered essential for EBV-mediated B 
cell transformation initially from studying the lack of transforming ability of EBNA2-
deficient EBV strain P3HR-1 (56).  EBNA2 contributes to EBV-mediated transformation by 
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regulating transcription of both cellular and viral genes, such as CD21, CD23, BATF, LMP1, 
and LMP2A (2, 57, 114, 167).  The transactivating function of EBNA2 is mediated through 
its ability to interact with downstream target of Notch, Jκ-recombination-binding protein 
(RBP-Jκ), and abolish RBP-Jκ-mediated transcriptional repression (114, 145, 332, 438).  
Other than Notch, EBNA2 has also been suggested to regulate signaling pathways mediated 
by other transcriptional factors, such as STAT3 (269). 
 
EBNA-LP 
EBV-encoded nuclear antigen leader protein (EBNA-LP) is not essential for EBV-
mediated transformation but is important for the outgrowth of EBV-transformed B cells (56, 
243, 353).  The main function identified so far for EBNA-LP is that it interacts with the acid 
activation domain of EBNA2 and cooperate with EBNA2 in RBP-Jκ-mediated transcriptional 
activation of cellular and viral genes (120, 281).  Moreover, it has been shown that EBNA-
LP’s activity may be mediated through the interaction with Sp100 (222).  Three 
evolutionarily conserved regions of EBNA-LP are important for its nuclear translocation and 
functions, and EBNA-LP interacts with the tumor suppressor genes p53 and retinoblastoma 
(Rb) (299, 368).  EBNA-LP also binds the anti-apoptotic protein Bcl-2 and its EBV 
counterpart BHRF1, indicating that it regulates apoptosis in EBV-infected cells (247).  
Interestingly, a recent study showed that a truncated form of EBNA-LP is expressed in some 
BL cells infected with EBV strains defective for EBNA2.  The truncated EBNA-LP induced 
resistance to caspase-mediated apoptosis through its interaction and sequestration of 
phosphatase 2A (PP2A) (101).  These findings further suggest that in addition to cooperating 
18 
 
with EBNA2, EBNA-LP has independent functions to contribute to EBV-mediated 
transformation.  
 
EBNA3A, EBNA3B, EBNA3C 
Similar to EBNA2 and EBNA-LP, EBNA3s are only expressed in type III latency of 
EBV infections.  In vitro infections using recombinant EBV have shown that EBNA3A and 
EBNA3C are essential for EBV-mediated B cell transformation but EBNA3B is dispensable 
(382, 383).  The EBNA3s repress EBNA2/EBNA-LP-mediated RBP-Jκ transactivation 
through competing for binding with RBP-Jκ (166, 322, 400, 435).  EBNA3A has been shown 
to repress the EBV Cp promoter in both epithelial and B cells (53).  The roles of EBNA3B in 
EBV infection is unclear since it’s not required for EBV-mediated transformation, but it may 
be important for maintaining viral latency by regulating chemokine receptor CXCR4 (43).  In 
cooperating with RAS, EBNA3C can disrupt cell cycle checkpoints and transform rodent 
embryonic fibroblast (292, 293).  The transforming activity of EBNA3C may reflect its 
ability to interact with cellular proteins that modulate gene transcription and apoptosis, such 
as histone deacetylase 1 (HDAC1), p53, Rb, and cyclin A (195, 292, 314, 426).  Despite the 
aforementioned negative effects on EBNA2, EBNA3C can also induce LMP1 transcription in 
conjunction with EBNA2 (436).  A recent study reported that EBNA3A and EBNA3C co-
operatively regulate BL pathogenesis through downregulation of the pro-apoptotic tumor 
suppressor gene Bim (9). 
   
EBERs 
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EBER1 and EBER2 are two small nonpolyadenylated, non-coding, RNAs that are 
expressed in all types of EBV latency and thus serve as good targets for detection of EBV 
infection using in situ hybridization (118, 144).  Although the EBERs are not essential for 
EBV-mediated B-cell transformation, they are shown to be able to enhance the tumorigenic 
potential of B cells in cell culture and in immunodeficient mice by preventing apoptosis (196, 
329, 423).  Similarly, overexpression of EBERs can also increase the resistance of NPC cell 
lines to apoptosis (273, 416).  A recent study suggests that despite their structural similarities, 
EBER2 contributes to B-cell transformation more significantly than EBER1 (417).   
The effects of the EBERs on apoptosis may be due to its ability to assemble into 
ribonucleoprotein complexes and bind with double-stranded RNA-activated protein kinase 
PKR (272, 370).  PKR has been known to induce pro-apoptotic pathways (68).  By binding 
and inhibiting PKR activity, EBERs may increase the tumor cell’s resistance to apoptosis, 
and promote viral persistence (272, 348).  However, this hypothesis has been recently 
challenged by a study which showed that EBERs are not able to block PKR-induced protein 
phosphorylation mediated by interferon (328).  This result argues that EBER-mediated 
inhibition of apoptosis is not due to direct interaction with PKR.  EBERs may also provide 
anti-apoptotic signals by inducing the expression of anti-apoptotic factor Bcl-2, and 
contribute to tumorigenesis by inducing expression of pro-proliferative factors, such as IL-10 
in B cells and insulin-like growth factor 1 (IGF-1) in EBV-associated NPC or gastric 
carcinoma (157, 158, 194, 196).   
Due to their status as the most abundant transcripts in EBV-infected cells, a recent 
study has taken advantage of this fact to develop shRNA fusion transcripts controlled by the 
EBERs promoter (49).  SiRNAs processed from these fusion transcripts exhibit stronger 
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efficiency of knocking down target genes without activating double-stranded RNA-
dependent protein kinase activity.  This strategy may be used for more effective gene 
therapy, especially in EBV-infected cells. 
 
BARTs 
BamHIA rightward transcripts (BARTs) are a group of abundantly expressed RNAs 
that are highly spliced and encoded by the BamHIA region of the EBV genome (331, 359).  
The BARTs were first identified and characterized in NPC and were shown to be highly 
abundant compared to transformed lymphocytes (44, 138, 177, 331).  However, using 
partially-deleted EBV cosmid recombinants, the BARTs were shown to not required for 
EBV-mediated latent infection or B-cell transformation (323).   
Three potential open reading frames (ORFs), rk103 (RPMS1), rb2 (A73), and 
rkbarf0, are located in BARTs.  Transcripts containing RK-BARF0 and RB2 are prevalently 
expressed in NPC tumors (331).  Although the protein products of these ORFs have not been 
conclusively identified in vivo, despite the detection of specific antibodies in NPC patients, 
recombinant technologies have been used to evaluate their potential function (106).  RK-
BARF0 has been found to interact with human I-mfa domain-containing protein (HIC), 
epithelin, scramblase, Notch3, and Notch4 by yeast-two-hybrid screenings (200, 378).  RK-
BARF0 interacts with both processed and unprocessed Notch4 but only induces the nuclear 
translocation of unprocessed Notch4.  Moreover, interaction of RK-BARF0 with Notch 
induces proteasome-mediated degradation of Notch, which may explain the low level of 
endogenous Notch expression in EBV-positive cell lines (378).  These results indicate that 
RK-BARF0 may contribute to EBV-mediated tumorigenesis by regulating Notch pathways.  
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Interestingly, RK103 may also contribute to Notch regulation by interacting with RBP-Jκ, a 
Notch target, to inhibit transactivating activities of NotchIC or EBNA2 (433).  Furthermore, 
it has been reported that overexpression of RK103 exhibits oncogenic potential in 293 cells 
and in nude mice (208).   
RB2 has been shown to be a cytoplasmic protein which can interact with receptor for 
activated protein kinase C (RACK1), a modulator of protein kinase C (PKC) or Src kinases 
(359).  Interestingly, a recent study suggests that multiple polymorphisms in the rb2 gene 
may be correlated with NPC development (434).  Another transcript product of BARTs, 
BARF1, is expressed both as an early gene in the lytic cycle or as a secreted latent protein in 
EBV-associated NPC (62).  Overexpression of BARF1 displays oncogenic activity in B cells, 
rodent fibroblasts and monkey primary epithelial cells by stimulating the cell cycle (335, 
350, 351). 
 
EBV and MicroRNAs 
EBV is the first virus to be identified encoding microRNAs (miRNAs) (301).  
Multiple approaches have been applied to identify EBV miRNAs, including computational 
prediction, microarray analysis, and small RNA cloning (38, 115, 300, 301, 439).  To date, 
approximately 30 EBV miRNAs have been identified, mainly distributed within two areas, 
BARTs introns and BHRFs transcripts.  Similarly to the BART transcripts, the expression of 
BART miRNAs is tissue-specific, BART miRNAs are expressed at high level in latently 
infected epithelial cells, such as NPC or GC, but at much lower level in B cells (38, 191).  In 
contrast, the BHRF miRNAs are expressed in a latency type-dependent manner.  BHRFs 
miRNAs are produced from an intron within the EBNA2 transcript and expressed at high 
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levels in B cells in type III latency but are undetectable in B cells or epithelial cells of type I 
or II latency (38).  During transcription, miRNAs are processed prior to the splicing reaction 
and a specific form of transcript favors miRNA production.  Therefore, the BART structure 
may account for the difference in EBV miRNA abundance (71).  Interestingly, the induction 
of lytic replication enhances the expression of many EBV miRNAs (38, 422). 
Several studies have suggested that EBV miRNAs may contribute to EBV 
tumorigenesis by targeting both viral and cellular genes.  BART miRNAs have been 
suggested to promote cancer development and viral latency by regulating expression of 
LMP1 and viral DNA polymerase BALF5, respectively (20, 224).  EBV miRNAs also 
provide cancer cells with immune-evasive and survival signals by targeting cellular genes 
involved with the immune response and apoptosis, such as CXCL-11, MICB, and PUMA 
(50, 271, 418). 
EBV infection also has significant effects on cellular miRNA expression (110).  EBV 
infection has been shown to induce expression of human oncogenic miRNAs, or oncomirs, 
like miR-155 and miR-146a to regulate cellular transcription machinery (230, 267, 427).  It 
has been suggested that EBV regulates the expression of cellular miRNAs through LMP1-
activated transcriptional factors, such as NF-κB (103, 267, 316).  These quickly-
accumulating data suggest that EBV can regulate expression of viral and cellular genes 
through novel miRNA pathways to promote tumor progression and maintain viral latency. 
 
EBV-Associated Diseases and Malignancies 
Infectious Mononucleosis 
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Primary infection of EBV, through oral transmission during childhood, is normally 
asymptomatic.  However, if the primary infection is delayed until adolescence or early 
adulthood, half of the patients develop benign lymphoproliferative disease infectious 
mononucleosis (IM) (277).   IM has been shown to be a significant risk factor for EBV-
associated Hodgkin’s lymphoma with about 1 in 1,000 patients with IM developing HL later 
in life (139, 164).  During IM, complex infection involving multiple strains of EBV occurs in 
the oral cavity, peripheral blood lymphocytes, and the cell-free plasma (356).  Patients with 
IM shed high titers of infectious virus and could suffer clinical symptoms with various 
degrees of severity, including fever, pharyngitis, headache, malaise, lymphadenopathy, and 
splenomegaly (55, 80).  These symptoms are mainly due to hyperexpansion of CD8+ T cells 
and subsequent cytotoxic immune response, such as induction of IFN-γ and TNF-α,  induced 
by EBV-infected B-lymphocytes (4, 40, 137).  Polymorphisms in the interleukin-10 gene 
have been linked to the severity of lymphoproliferation of symptomatic primary EBV 
infection (124).  Recent studies showed that class I human leukocyte antigen (HLA)-A1 fails 
to present LCL-expressed, highly immunogenic peptides of EBV latent antigens and thus 
represent one of the risk factors of acute IM and Hodgkin lymphoma (29, 279).  Moreover, 
class I HLA polymorphisms within HLA-A1 and HLA-A3 was suggested to predispose 
patients to development of IM upon primary EBV infection (248). 
 
Chronic Active EBV Infection 
In most IM cases, the primary infection is controlled by immune system.  However, 
in some young patients recurrent fever, lymphadenopathy, hepatosplenomegaly, chronic 
fatigue, and other symptoms occurs even several years after the primary infection (289).  
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Patients with chronic active EBV infection have very high EBV genome loads in the 
peripheral blood mononuclear cells (PBMC), high titers of antibodies against EBV-encoded 
antigens, and expression of EBV proteins and transcripts in the affected tissues (127, 237, 
342).  It has been suggested that defects in cytotoxic activity of T cells and natural killer 
(NK) cells contribute to the occurrence of chronic active EBV infection (96, 169, 388).  A 
recent study showed that EBNA1-specific CD4 (+) T cells are capable of killing EBV-
infected NK and T cells derived from patients with chronic active EBV infection, indicating 
the potential of this approach in vaccine design and immunotherapy of EBV infection (64). 
 
Oral Hairy Leukoplakia 
Characterized by productive infection of EBV in the squamous epithelial cells of the 
lateral tongue border, oral hairy leukoplakia (OHL) often develops in HIV-infected or 
otherwise immunocompromised patients and is the only known pathological manifestation of 
permissive EBV infection in epithelial cells (112).  Without obvious symptoms, OHL 
develops as white or gray patch on the tongue or the inside of the cheek and is identified 
histologically by epithelial acanthosis, lack of inflammatory infiltrate, and hyperkeratosis 
(133).  It has been shown that OHL is infected by multiple EBV strains characterized by 
sequence variation within the LMP1 gene (355, 397, 399).  In addition to lytic gene products, 
the EBV latent genes EBNA1, EBNA2, and LMP1 are also detected in OHL lesions, as well 
as signaling pathways contributing to EBV transformation, such as LMP1-induced NF-κB 
and JNK activation (398, 406, 407).  The EBV glycoprotein BMRF-2 is highly expressed in 
OHL epithelium and is thought to play an important role in cell-to-cell spread of EBV within 
the oral epithelium through association with various integrins (419, 420). 
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Virus Associated Hemophagocytic Syndrome 
Haemophagocytic syndrome (HPS) is a rare but often fatal disease despite treatment.  
HPS is caused by dysregulations in T-cell and NK-cell functions, resulting in activation and 
proliferation of lymphocytes with out-of-control haemophagocytosis and cytokine 
overproduction (61, 363).  Characterized by clinical symptoms such as fever, 
hepatosplenomegaly, liver dysfunction, cytopenias, and hyperferritinaemia, HPS is 
associated with viral infections, including EBV, human cytomegalovirus (HCMV), human 
herpesvirus 8 (HHV8), HIV, influenza virus, and hepatitis virus (88, 325).  Among all of the 
viruses associated with this disease, EBV is the most common triggering agent and EBV-
associated syndrome results in the worst prognosis.  In EBV-associated HPS, EBV infects 
CD8+ T cells and results in the lack of production of EBV-specific cytotoxic T cells, 
followed by severe cytokine storm and organ dysfunctions (154, 178).  Normally occurs 
during reactivation, EBV-associated HPS also develop with other EBV-caused diseases, such 
as IM, chronic active infection, and NK T-cell lymphoma (5, 51, 286).  It has been recently 
suggested that LMP1-induced ATF5 may contribute to the pathogenesis of HPS by 
transcriptionally downregulating signals for lymphocyte activation molecule-associated 
protein (SAP) to enhance Th1 cytokine secretion in T cells (52). 
 
X-linked Lymphoproliferative Syndrome 
X-linked lymphoproliferative syndrome (XLP; also called Duncan’s disease) is a rare 
immunodeficiency disease identified by its inability to control EBV infection-induced 
immune response (121, 219).  XLP patients exhibit polyclonal B-cell proliferation, defective 
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NK cell cytotoxicity and prolonged cytotoxic T-cell activity, resulting in often fatal 
infectious mononucleosis and malignant lymphoma in response to EBV infection (119, 276, 
344).  The phenotype of XLP is thought to result from defective-mutations within several 
genes on the human X chromosome, including SAP and X-linked inhibitor-of-apoptosis 
(XIAP), lead to defects in the activity of NK-cells to kill EBV-infected B cells (275, 294, 
319).  A recent study identified a homozygous missense mutation of IL-2-inducible T cell 
kinase (ITK) in two Turkish girls who suffered fatal immunoproliferative disorders following 
EBV infection, resembling the pathogenesis of XLP (148). 
   
Post-Transplant Lymphoproliferative Disorder 
Solid organ transplant patients who receive immunosuppressive therapy are 
vulnerable to the development of post-transplant lymphoproliferative disorders (PTLD), 
including a variety of B-cell diseases which are mostly EBV-positive (408).  Although 
capable of developing much later after the transplantation, most PTLDs occur within the first 
year of allografting with the most severe immunosuppression and the weakest cytotoxic T-
cell activity.  The majority of PTLD tumors are in type III latency, with expression of all 
latent genes, although occasionally lytic gene of EBV or more intermediate patterns can also 
be detected (270, 381, 428).  Data from studying gene sequencing and rearrangements of 
immunoglobulin (Ig) variable regions showed that in PTLDs EBV can infect B cells at any 
stage of differentiation, including naïve cells, memory cells, germinal center B cells, or even 
B cells possessing hypermutations of Ig (15, 28, 381).  These novel EBV infections of non-
naïve B cells in immunocompromised patients may create a pool of EBV-infected B cells 
with permanent transforming potential by trapping these infected cells into the “growth 
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program” of EBV gene expression (15, 297).  An in vitro study showed that EBV infection 
results in transcriptional and posttranscriptional defects of surface immunoglobulin, 
indicating that EBV infection contributes to the development of PTLD by rendering B-cell 
receptor (BCR)-deficient and pre-apoptotic germinal center B cells independent from 
survival signals normally supplied by the BCR (22).  Several genetic mutations are 
associated with PTLD, including c-myc and bcl-6 (41, 214, 374, 428). 
 
Gastric Carcinoma 
EBV is associated with approximately 10% of ordinary gastric carcinoma (GAC), 
while some rare subtypes are associated with EBV more frequently, such as 
lymphoepithelioma-like GAC (80%) and post-operative gastric stump carcinoma (35%) (152, 
369).  EBV-associated GAC normally localize to the upper stomach area, and EBV infection 
is considered a late event in GAC development due to the lack of detection of EBERs in the 
preneoplastic cells (442).  EBV-associated GAC exhibits a unique latency expression pattern, 
with both latent and lytic genes being expressed (143).  Moreover, only LMP2A, but not 
LMP1 and LMP2B, is expressed in EBV-associated GAC (364).  A recent study showed that 
LMP2A induces the expression of survivin through NF-κB pathway in GAC cell lines, 
potentially providing survival advantage for EBV-associated GAC (134).  The BARF1 gene 
is also expressed in GAC and can induce expression of cyclin D1 and increase ratio of Bcl2 
to Bax to provide anti-apoptotic properties for GAC cells (403, 412, 441).  Increasing amount 
of evidence have suggested that frequent aberrant methylations of CpG island occur in a 
global but also target-specific manner in EBV-associated GAC (173).  Multiple genes are 
downregulated through methylation-mediated silencing mechanisms, including p14, p16, 
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p73, PTEN, HOXA10, and RASSF2A (135, 172, 246, 333, 393).  Interestingly, despite these 
implications that EBV provide survival advantages to GAC, EBV infection has been linked 
to better patient survival (394).    
 
Multiple Sclerosis 
EBV has been associated with multiple sclerosis (MS) by epidemiological studies 
investigating the relationship between infectious mononucleosis and MS, a complex 
inflammatory CNS disease (235, 373).  Elevated humoral and cellular immune response 
against EBNA1 has been found in MS patients (233, 235).  A strong correlation between 
EBV infection and MS was recently demonstrated by the discovery of selectively-expanded 
EBNA1 specific CD4+ Th1 cells that also possess the ability to cross-recognize MS-
associated myelin antigens to trigger immune response (234).  It has also been suggested that 
potential genetic defects of CD8+ T cells result in decreased T cell reactivity to EBV-
infected LCLs and predispose patients to MS by accumulating EBV-infected B cells in the 
CNS of MS patients (298).  Characterized by high titers of anti-EBV antibodies, increased 
EBV viral load and expression of EBV DNA/RNA, EBV infection has also been linked to 
other autoimmune diseases, including systemic lupus erythematosus (SLE), primary 
Sjögren’s syndrome (pSS), and rheumatoid arthritis (RA) (304, 384).  
 
Burkitt’s Lymphoma 
EBV-associated Burkitt’s lymphoma (BL) can be basically divided into three 
categories: endemic, sporadic, and AIDS-associated.  BL is 100% EBV-positive in New 
Guinea and areas of Africa where malaria is holoendemic, and is approximately 85% EBV-
29 
 
positive in Brazil and North Africa where incidence of BL is lower (16, 34, 36, 238, 305).  In 
these areas, EBV-associated BL is the leading cause of childhood cancers and normally 
develops at extranodal sites in the jaw during molar eruption or in the CNS (3, 190).  Only 
15% of sporadic BL in the developed countries are associated with EBV and these cases 
normally develop at a later age and frequently present with an abdominal mass and 
occasionally as leukemia (238).  Approximately 30-40% of AIDS-associated BLs are 
associated with EBV.  These tumors appear as small B cell lymphoma in adult HIV-carriers 
and also often occur as the first sign of AIDS development in relatively immunocompetent 
patients (98, 190).    
All BLs appear to be monoclonal and may originate from the germinal center B cells 
due to expression of germinal centroblasts’ markers, such as CD10, CD77, and Bcl6 (75, 
311).  It has been suggested that HIV-infection and holoendemic malaria may contribute to 
BL development by inducing lymphadenopathy and germinal center activity, or recruiting 
EBV-infected B cells into germinal center reactions (12, 23).  BL can have one of three 
characteristic chromosomal translocations that place the c-myc oncogene under the control of  
the Ig heavy chain promoter on chromosome 14 or one of the light chain loci on chromosome 
2 or 22 (58).  These translocations result in deregulation of c-MYC expression and are 
important for BL proliferation (123, 213, 303).  This is especially critical for BL 
pathogenesis considering that EBV-associated BL tumors have type I latency pattern with 
expression of only EBNA1 but not major oncoproteins EBNA2 or LMPs (303, 327).  
However, EBNA1 does seem to provide survival signals for BLs in addition to its normal 
function of maintaining viral episomes (183).  Interestingly, in a subset of BLs where type III 
latency expression pattern is mostly retained, EBNA2 is deleted from the viral genome (181).   
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Transcriptional silencing of tumor suppressor genes are often found in BLs in 
addition to mutations of p53, p14, Bax, and Rb, as well as methylation-mediated inhibition of 
p16, p73, PUMA, and cyclin D2 (102, 221, 352).  Upregulations of several oncogenes, such 
as TCL1 and MDM2, have also been reported in BLs (193, 220). 
 
Hodgkin Lymphoma 
A common cancer in developed countries, incidence of Hodgkin lymphoma (HL) 
peaks at young adults aged 15-34 years and more prevalent in male (163).  HL is an unusual 
tumor, where the neoplastic cells only account for 1% of the cells within the tumor (99).  
Neoplastic cells in HL, including mononucleate Hodgkin cells and multinucleate Reed-
Sternberg cells (collectively called HRS cells), are surrounded by non-malignant 
inflammatory infiltrate.  Different types of infiltrate define HL into three subtypes: nodular 
sclerosing (NS), mixed cellularity (MC), and lymphocyte-depleted (LD) subtypes.  
Approximately 40% and nearly 100% of HL cases are associated with EBV-infection in 
developed and developing countries, respectively (147).  And individuals with a prior history 
of IM have higher risk of developing HL, further indicating the importance of EBV-infection 
in HL (109).  Interestingly, in developed countries EBV-associated HL cases include most 
MC and LD subtypes but only a minority of the NS subtype, which makes up for the “peak” 
group of young adults.  This phenomenon reflects the fact that EBV-associated HL cases are 
most frequent in the older population of developed countries.  In developing countries, 
however, HL cases are most frequent in childhood without the peak in young adults (13, 
147).  Cytokines released from both HRS and inflammatory infiltrate cells, such as IL-1, IL-
6, TGF-β, and TNF-α result in the clinical symptoms of HL (187). 
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In EBV-positive HLs, the virus is found only in malignant HRS cells.  Genotyping of 
Ig V locus has identified that HRS are likely derived from nonfunctional postgerminal center 
B cells that atypically survived the GC reaction (26, 27, 176, 199).  EBV-infected HRS cells 
exhibit a type II latency expression pattern and have no chromosomal abnormalities (8, 409, 
410).  EBV-positive HLs demonstrate constitutive activation of NF-κB, and PI3K pathways, 
which are potentially induced by LMP1 or LMP2A to ensure the proliferation and survival of 
HRS cells (19, 69, 307, 343).  Interestingly, EBV-negative HLs also show constitutive NF-
κB activities by inactivating inhibitor of κBα (IκBα) or amplifying the REL gene (198).  
Deregulation of cellular genes expression have also been shown in HL, including increased 
IL-10, STAT1, STAT3, and Bcl-3, as well as decreased p27,p53, CDK6, cyclin E, and BCL-
XL (100, 306).  
 
Nasopharyngeal Carcinoma 
Nasopharyngeal carcinoma (NPC) is a subset of gastric adenocarcinomas and certain 
salivary-gland carcinomas (309).  Its anatomical location is in the upper throat and directly 
behind the nosal cavities, and the carcinoma arises from the epithelium lining the surface 
and subterranean chambers of the nasopharynx (162, 395).  The World Health Organization 
(WHO) classifies NPC into three subtypes based on the degree of differentiation: keratinizing 
squamous cell carcinoma (type 1), non-keratinizing carcinoma (type 2), and undifferentiated 
carcinoma (type 3), which is the most frequent form of the disease and also shows the most 
consistent association with EBV infection (309, 347).  EBV-associated NPC has specific 
geographical and ethnic distribution.  In most part of the world, including Europe and North 
America, the incidence of NPC is lower than 1 case per 100,000 human population.  
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However, the frequency of NPC incidence increases dramatically in Arctic region, South 
China, and Southeast Asia, with 15-30 cases person 100,000 population per year (430).  In 
Chinese Cantonese males in Hong Kong or Guangzhou, the incidence rates can even climb 
up to a jaw-dropping 150 cases per 100,000 population per year (129).  Notably, the 
incidence rate of NPC remains high in populations moved from high-incidence areas, as well 
as in their descendants, regardless of where they live (132).  This suggests a genetic 
predisposition to the disease in addition to environmental triggers such as salted fish 
consumption and exposure to chemical carcinogens (1, 430).  EBV association with more 
differentiated forms of NPC has also been shown in these high-incidence areas (295).  
NPC appears as a mixture of malignant epithelial cells and a prominent, non-
malignant, EBV-negative lymphocytic infiltrate, which likely contributes to tumor 
propagation by producing cytokines (297, 429).  NPC cells also express immune regulatory 
factors, indicating the functional interaction between NPC cells and surrounding lymphoid 
cells (4).  EBV-associated NPC is in type II latency which includes the expression of 
EBNA1, EBERs, BARTs transcripts, LMP1 (in ~50% of cases), and LMP2A (in ~45% of 
cases) (130, 297, 309, 312, 429).  It has been shown that EBV-associated NPC has 
monoclonal infection of EBV, indicating that EBV infection occurs before the clonal 
expansion of malignant cells (311).  Some NPC cells may spontaneously undergo productive 
replication and linear EBV genome can be detected in NPC patients as well as viral lytic 
antigens (128). 
NPC tumor cells express human leukocyte antigen (HLA) class I and II that process 
antigens efficiently (188, 203).  HLA haplotype contributes to NPC pathogenesis as genes 
linked to HLA are associated with different degrees of risk for NPC development (231).  
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HLA haplotypes HLA-A2, BW46, A19, and B17 of class I, as well as HLA-DR β10803 of 
class II are associated with an increased risk for NPC, while HLA-A11 and HLA-B13 of 
class I are associated with a decreased risk for NPC (73, 190).  A distinctive predominance of 
specific LMP1 strains in endemic NPC has been identified with sequence changes in HLA-
restricted epitopes.  This finding suggested that LMP1 evade immune recognition by having 
specific sequence variation in NPC (73).  The association between HLA haplotypes and NPC 
prevalence may explain the high incidence rates of NPC in Chinese descendant who no 
longer live in high-risk areas. 
Other than HLA haplotypes, other genetic factors could be important for EBV 
infection and NPC development.  This is supported by the fact that EBV is monoclonal in 
malignant cells and also appears in pre-malignant lesions in the nasopharynx (296).  Multiple 
genetic alterations, such as deletions or methylations, have been reported in NPC, locating in 
chromosomes 3p (RASSF1A), 9p (p16), 11q, 13q, and 14q (280, 429).  Interestingly, 
mutations of p53 are detected in NPC tumors passaged in nude mice but much more 
infrequently in primary NPC samples, indicating that p53 mutations are not essential for NPC 
development (74). 
 
Therapeutic Approaches 
Traditional treatments of EBV-associated diseases include antiviral agents, immune 
modulators, and chemotherapeutic drugs.  Two major directions of therapeutic approach are 
being developed to treat EBV-associated tumors, including pharmacological and 
Immunological-based therapies.  In pharmacological methods, one approach is to induce 
EBV lytic cycle in order to enhance cytotoxic immune response.  For example, 
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demethylating agent 5-azacytidine can de-repress lytic cycle of EBV to induce EBV-encoded 
kinases that subsequently activate nucleoside analogue gancyclovir for cytotoxic activities 
(42).  Delivery of EBV immediate early genes may elicit similar effects (7, 84, 156).  More 
selective approach was experimented using EBNA1-responsive gene-therapy construct to 
express cytotoxic proteins or p53 in tumor cells (210).  Approaches directly targeting 
individual EBV proteins have also been tested using single-chain antibodies, antisense RNA, 
and small chemical compounds or EBNA2-TAT peptide inhibiting NF-κB and RBP-Jκ 
pathways (37, 83, 184, 302).   
Immunotherapy approach has been proven successful firstly in preventing bone-
marrow-transplant patients from developing PTLD.  Effector T cells were prepared from the 
bone marrow donor by autologous LCL stimulation and expansion ex vivo before being 
infused to the recipient to provide EBV-specific, mostly EBNA3s-specific, cytotoxicity 
(324).  Similar adoptive immunotherapy has also been developed in solid organ transplant 
cases and showed promising results (338).  Similar methods are also being developed to 
target other EBV proteins that are less immunogenic, such as LMPs (396).  Dendritic cells 
pulsed with LMP2 epitopes have been used to treat EBV-positive nasopharyngeal carcinoma 
patients with noticeable CD8+ T-cell responses (217).  Alternative treatments using 
monoclonal antibodies to target EBV receptor CD21 or B-cell antigen CD24 and CD20 have 
also been used to try to eliminate EBV-infected B cells (287).    Moreover, anti TNF-α agents 
have been used to treat X-linked lymphoproliferative syndrome (288). 
 
EBV Vaccines 
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The development of EBV vaccines has been hampered by some limitations and 
concerns.  The nature of EBV’s life cycle and tumorigenesis make it difficult to design 
vaccines delivered to people at risk of developing malignancies such as NPC or 
lymphoproliferative diseases before primary infection.  Moreover, potential antigens 
expressed by EBV during latency normally have oncogenic potentials and will be evaluated 
as vaccine candidates with great skeptism (189, 266).  However, with increasing 
understandings of EBV biology as well as immunological controls of EBV-associated 
diseases, multiple vaccines have been under development for prophylactic protection (IM) 
and therapeutic purposes (Malignancies) (229).  Recombinant gp350 subunit vaccine has 
been shown to induce neutralizing antibody response to prevent the development of IM 
caused by EBV-infection after phase I and II clinical study (161, 268, 360).  Single peptide-
based vaccine using CD8+ T-cell epitope from EBNA3 conjugated with tetanus toxoid as a 
source of CD4+ T-cell help has shown positive results, after phase I trial, in preventing IM 
without predisposing recipients to diseases (78).  However, the HLA diversity across human 
population will limit the efficacy of vaccines with single peptide.  This problem can 
potentially be solved by using recombinant virus technique to express multiple epitopes at 
once (111).  A recent mice study showed that a tetrameric vaccinia virus-based vaccine 
expressing epitopes from gp110, gp350, EBNA2, and EBNA3C elicited the production of 
neutralizing antibodies and EBV-specific T-cell responses (225).  This “cocktail” strategy 
may prove to be efficient against both EBV primary infection and EBV-associated 
malignancies. 
 
Epidermal Growth Factor Receptor in NPC 
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Upregulation of the epidermal growth factor receptor (EGFR) has been detected in 
over 70% of EBV-associated NPC samples and correlated with LMP1 expression level (291, 
349, 437).  Moreover, the level of EGFR expression is positively associated with the stage of 
the disease (291).  Treatment with EGFR tyrosine kinase inhibitors induces cell cycle arrest, 
inhibits cell proliferation of NPC cell lines, and exhibits potent antitumor effects on NPC 
xenografts using in vivo mouse model (366, 404, 421, 440). 
EGFR is a member of the ErbB receptor tyrosine kinase family which includes EGFR 
(ErbB-1), HER2/c-neu (ErbB-2), HER3 (ErbB-3), and HER4 (ErbB-4).  Upon ligand 
binding, ErbBs undergo dimerization, autophosphorylation, activation, and subsequently 
degradation/turnover from an originally inactive conformation (86, 432).  Multiple signaling 
pathways are activated downstream of EGFR, including Ras/MAPK, Src kinases, 
JAKs/STATs, and PI3K-AKT pathways (170).  Deregulated EGFR signaling has been 
associated with tumor progression, invasion, and metastasis (411).  EGFR signaling has been 
shown to be targeted by oncogenic viral proteins to regulate tumorigenesis, including v-
ErbB, E5, and HBVx (254).  EGFR also serves as cellular receptor for HCMV entry and 
signaling (405).   
One important mechanisms by which EGFR becomes active and potentially 
oncogenic is through activating mutations (431).  Numerous activating mutations have been 
identified in EGFR that can affect ligand binding, receptor dimerization and phosphorylation, 
as well as its enzymatic activity and substrate specificity (318).  However, somatic mutations 
were not detected in a comprehensive sequencing analysis in NPC (202).  This indicates that 
alternative mechanisms, such as amplification of EGFR found in NPC, play major roles in 
NPC development.  EGFR was previously shown to be induced by LMP1 in epithelial cell 
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line C33A at transcriptional level (250, 251, 253).  This transcriptional upregulation was 
found to be mediated by a novel NF-κB complex comprised with p50 homodimer and Bcl-3 
(379, 380).  LMP1-induced EGFR may play a very important role in EBV tumorigenesis and 
is a prime target for development of therapeutic strategies.  Interestingly, in current EGFR-
targeted treatments using chemical inhibitors and monoclonal antibodies, patients with 
elevated EGFR expression level generally exhibit better response (70, 136, 259).  This 
further suggests NPC patients could more likely benefit from EGFR-specific treatments.  
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OBJECTIVES 
EBV LMP1 is the main oncoprotein of EBV during latent infection.  LMP1 is 
required for EBV-mediated B cell transformation and overexpression of LMP1 results in 
deregulated proliferation and transformation of rodent fibroblast cells.  The oncogenic 
potential of LMP1 is due to multiple signaling pathways mediated through two major 
signaling domains of LMP1, CTAR1 and CTAR2.  CTAR1 is capable of inducing cell 
transformation while CTAR2 is dispensable, indicating that signaling transduction 
downstream of CTAR1 are critical for LMP1-mediated transformation and ultimately, EBV-
associated tumorigenesis.  The goal of the studies presented in this dissertation is to evaluate 
several signaling pathways engaged by LMP1-CTAR1 to regulate cellular gene expression 
and cell transformation focused on CTAR1-specific induction of EGFR. 
 
Aim 1.  LMP1 induces EGFR upregulation in epithelial cells through STAT3 activation 
and Bcl-3 induction.   
In C33A cells and NPC, LMP1-CTAR1 induces EGFR transcriptional expression 
through a transactivating complex comprised of p50 and Bcl-3.  The effects of LMP1 on Bcl-
3 expression and translocation in C33A cells were analyzed in this study.  The connection 
between CTAR1-mediated STAT3 activation and EGFR upregulation was established using 
chemical inhibitors and chromatin-immunoprecipitation analysis. 
Aim 2.  LMP1 modulates distinctive NF-κB pathways through CTAR1 to regulate 
EGFR expression. 
In addition to EGFR induction, CTAR1 also activates multiple forms of NF-κB.  
Mouse embryonic fibroblasts (MEFs) defective for different NF-κB effectors were used in 
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this study to evaluate the effects of NF-κB pathways on CTAR1-mediated EGFR induction.  
MEFs defective for NF-κB effectors or different TRAFs were also used to identify the factors 
involved with CTAR1-induced p50 activation. 
Aim 3.  Effects of CTAR1 on signaling transductions involved with EGFR and STAT3. 
In addition to increased EGFR expression, we show that overexpression of CTAR1 
also induced EGFR activation intrinsically and in response to an EGFR ligand.  EGFR-
mediated STAT3 activation and potential downstream targets were evaluated.  Importantly, 
PKCδ was identified as the serine kinase of STAT3 in CTAR1-expressing C33A cells and 
was required for activation of ERK.  The effects o f PKCδ o n CTAR1-mediated 
transformation were tested using focus formation assay. 
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ABSTRACT 
Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) activates multiple 
signaling pathways.  Two regions, CTAR1 and CTAR2, have been identified within the 
cytoplasmic carboxy terminal domain that activates NF-κB.   C-terminal activating 
region 2 (CTAR2) activates the canonical NF-κB pathway which includes p50/p65 
complexes.  C-terminal activating region 1 (CTAR1) can activate both the canonical and 
noncanonical pathways to produce multiple distinct NF-κB dimers, including p52/p50, 
p52/p65, and p50/p50.  CTAR1 also uniquely upregulates the epidermal growth factor 
receptor (EGFR) in epithelial cells.  Increased p50-Bcl-3 complexes have been detected 
by chromatin precipitation on the NF-κB consensus motifs within the egfr promoter in 
CTAR1-expressing epithelial cells and NPC cells.  In this study, the mechanism 
responsible for the increased Bcl-3 has been further investigated.  The data indicate that 
LMP1-CTAR1 induces Bcl-3 mRNA and increases the nuclear translocation of both Bcl-3 
and p50.  LMP1-CTAR1 constitutively activates STAT3 and this activation was not due 
to induction of IL-6.  In LMP1-CTAR1-expressing cells, increased levels of activated 
STAT3 were detected by chromatin immunoprecipitation on STAT-binding sites located 
within both the promoter and second intron of Bcl-3.  A STAT3 inhibitor significantly 
reduced the activation of STAT3, as well as the CTAR1-mediated upregulation of Bcl-3 
and EGFR.  These data suggest that LMP1 activates distinct forms of NF-κB through 
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multiple pathways.  In addition to the canonical and noncanonical pathways, 
LMP1-CTAR1 constitutively activates STAT3 and increases Bcl-3.  The increased 
nuclear Bcl-3 and p50 homodimer complexes positively regulate EGFR expression.  
These results indicate that LMP1 likely regulates distinct cellular genes by activating 
specific NF-κB pathways. 
 
INTRODUCTION 
Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) is an essential factor 
in EBV-induced transformation and is expressed in many of the malignancies associated 
with EBV, including post-transplant lymphoma, Hodgkin’s disease, and nasopharyngeal 
carcinoma (NPC) (12, 28, 51, 66).  LMP1 is considered a constitutively activated 
member of the tumor necrosis factor receptor (TNFR) family and binds TNF associated 
factors (TRAFs) (27, 41, 44).  Two major signaling domains have been identified within 
the cytoplasmic C-terminal domain of LMP1, CTAR1 and CTAR2, that can activate 
NF-κB (25).  However, CTAR1 has several unique properties and is essential for 
transformation while CTAR2 is dispensable (34, 35).  LMP1-CTAR1 uniquely induces 
expression of the epidermal growth factor receptor (EGFR) at the mRNA level and this 
induction requires NF-κB and is mediated through the TRAF signaling pathway (41-43).  
Subsequent studies have identified other genes that are uniquely activated by 
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LMP1-CTAR1, including TRAF1 and EBI3 (14). 
The NF-κB transcription factors dimerize and bind NF-κB consensus sequences in 
cellular and viral promoters to regulate the expression of genes controlling inflammation, 
cell cycle regulation, apoptosis, and oncogenesis (21, 38).  There are five mammalian 
NF-κB family members including p50, p52, p65 (RelA), c-Rel, and RelB.  The 
activation of NF-κB family members is regulated through interactions with inhibitors of 
NF-κB (IκB), which sequester NF-κB members in the cytosol.  Activation of a kinase 
cascade that includes IKKα, IKKβ, and IKKγ results in phosphorylation, ubiquitination, 
and degradation of an IκB, leading to the release and nuclear translocation of NF-κB. The 
p50 and p52 precursor proteins, p105 and p100 respectively, can also function as IκB.  
Early studies initially showed that LMP1-CTAR1 activated multiple forms of NF-κB 
including p50/p65, p50/p52, and p50 homodimers and also greatly increased the 
processing of p100 to p52 in epithelial cells and the nuclear translocation of p50 (41, 48).  
It has subsequently been shown that the induction of processing of p100 represents 
another mechanism for activation of NF-κB.  This is considered the noncanonical 
NF-κB pathway and the activation of this pathway is specific for LMP1-CTAR1 (1, 15, 
33, 53).  Noncanonical activation of NF-κB requires IKKα and is mediated through the 
NIK kinase to induce processing of p100 and activate p52/relB.  Canonical activation 
requires IKKβ and IKKγ to activate p50/p65.  The activation of specific genes by LMP1 
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has been linked to the canonical and noncanonical pathways using engineered mouse 
fibroblasts (33).  MIP-2 was activated by canonical pathway, which is 
IKKβ/IKKγ-dependent.  Induction of the cellular chemokine, CXCR4, required IKKα 
and was considered activated by the noncanonical pathway.  An atypical pathway was 
also identified that was IKKβ dependent but independent of IKKγ and regulated 
expression of MIG and I-TAC. 
The link between LMP1-CTAR1 activation of unique genes and distinct forms of 
NF-κB was demonstrated in studies that showed that LMP1-CTAR1 induced the binding 
of NF-κB p50 and Bcl-3 to the NF-κB sites in the egfr promoter in C33A cells (59).  
LMP1 effectively induces the nuclear translocation of p50 and p50/p50 homodimers are 
the major NF-κB complex activated in LMP1-expressing cells and EBV-positive 
xenografted NPC tumors (48, 58, 59).  In addition, elevated levels of p50/p50 
homodimers and Bcl-3 are found in classical Hodgkin lymphoma and anaplastic 
large-cell lymphomas that are associated with EBV infection (37). 
In this study, the effects of LMP1-CTAR1 on Bcl-3 expression and EGFR 
induction were further evaluated.  LMP1-CTAR1 induced Bcl-3 transcription resulting 
in increased levels of nuclear Bcl-3.  The transcriptional activation of Bcl-3 required 
STAT3, which bound to sites within the Bcl-3 promoter and intron 2.  LMP1-CTAR1 
expression increased both the serine and tyrosine phosphorylations of STAT3 that are 
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indicative of activation.  These data indicate that LMP1 activates distinct forms of 
NF-κB through different pathways.  In addition to activation of the canonical and 
noncanonical pathways, LMP1-CTAR1 also activates p50/p50 homodimers by increasing 
expression of Bcl-3 through its effects on STAT3.   
 
MATERIALS AND METHODS 
Retrovirus production and transduction 
Recombinant retrovirus production and transduction were performed as previously 
described to establish C33A stable cell lines expressing full-length LMP1, CTAR1 
(1-231), CTAR2 (d187-351), or vector control pBabe (34).  Briefly, ~80% confluent 
293T cells were triple transfected using FuGEGE 6 transfection reagent (Roche) 
according to the manufacturer’s instruction with 5µg pBabe (vector), pBabe-HA-LMP1, 
pBabe-HA-1-231, or pBabe-HA-d187-351, and 5µg pVSV-G and 5µg pGag/Pol 
expressing plasmids.  After 24 hours incubation at 37°C, media were replaced with fresh 
media and cells were incubated at 33°C for another 24 hours.  Cell supernatant then was 
centrifuged at 1000g for 5 min to remove cell debris and virus-containing supernatant was 
collected.  C33A cells with ~70-80% of confluence were then transduced with clarified 
supernatant with 4µg/ml polybrene for 24 hours at 37°C. 
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Cell Culture and stable cell lines 
C33A cervical carcinoma cells were cultured in Dulbecco’s modified Eagle’s 
medium (Gibco) supplemented with 10% fetal bovine serum (Sigma) and 
antibiotic/antimycotic (Gibco) at 37°C with 5% CO2.  C33A stable cell lines expressing 
full-length LMP1, CTAR1 (1-231), CTAR2 (d187-351), or vector control pBabe were 
established by retroviral transduction followed by selection and passage in the presence of 
1µg/ml puromycin (Sigma). 
 
Fractionation of Cells 
After cultured cells reached ~80-90% confluence, cells were scrape harvested, 
washed once with cold phosphate-buffered saline (PBS, Gibco), centrifuged at 1000g, and 
lysed with RIPA buffer (20mM Tris-HCl [pH 7.5], 150mM NaCl, 1mM EDTA, 1% 
NP-40, 0.1% sodium dodecyl sulfate [SDS], 0.1% deoxycholic acid) supplemented with 
phenylmethylsulfonyl fluoride (PMSF), sodium orthovanadate (Na3VO4), protease and 
phosphatase inhibitor cocktail (Sigma).  Lysates were then clarified by centrifugation at 
13,000 rpm, 4°C for 15 min and supernatants containing whole cell lysates were removed 
to new tubes.  Nuclear extracts were made as previously described with slight 
modification (59).  Briefly, cells were scrape harvested, washed once with cold PBS, and 
lysed by incubation in a hypotonic buffer (20 mM HEPES, 10 mM KCl, 0.1 mM EDTA, 
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0.1 mM EGTA) supplemented with PMSF, Na3VO4, protease and phosphatase inhibitor 
cocktail (Sigma) for 15 min on ice.  Nonidet P-40 was then added to a final 
concentration of 1%, followed by 1 min of vortex.  Nuclei were pelleted by low-speed 
centrifugation at 1,200 rpm for 10 min at 4°C and the supernatant were collected as 
cytoplasmic fraction.  The nuclei fraction were purified using the Optiprep reagent 
(Sigma) as directed by the manufacturer, as previously described (58).  Nuclei were 
lysed with nuclear extraction buffer (20 mM Tris-HCl [pH 8.0], 420 mM NaCl, 1.5 mM 
MgCl2, 0.2 mM EDTA, 25% glycerol, PMSF, Na3VO4, protease and phosphatase 
inhibitor cocktail [Sigma]) with the salt concentration adjusted to 400 mM with 5 M NaCl.  
All lysates were stored at -80°C. 
 
Western Blot Analysis 
Protein concentration of cell lysates was determined using Bio-Rad DC protein 
assay system according to manufacturer’s instruction.  Equal amounts of protein were 
used for SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to Optitran 
(Schleicher and Schuell) for Western blot analysis.  Primary antibodies used include 
anti-p50, anti-β-actin, anti-GRP78, anti-STAT3, anti-PARP (Santa Cruz), anti-Bcl-3 
(Upstate Biotechnology), anti-phospho-STAT3 (Ser 727 and Tyr 705) (Cell Signaling), 
anti-phospho-EGFR (Tyr 1068) (BD Biosciences), and anti-HA tag (Covance).  A rabbit 
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antiserum raised against the carboxyl-terminal 100 amino acids of the EGFR fused to 
glutathione S-transferase (kindly provided by H. Shelton Earp) was used to detect total 
EGFR.  Secondary antibodies used to detect bound proteins include horseradish 
peroxidase-conjugated antimouse, antirabbit (Amersham Pharmacia), and antigoat 
(DAKO).  Blots were developed using Pierce Supersignal West Pico chemiluminescence 
system followed by exposure to film. 
 
Chromatin Immunoprecipitation (ChIP) Analysis 
ChIP analysis was performed using a ChIP kit (Upstate Biotechnology) according 
to manufacturer's protocol.  Briefly, cells were cultivated in 100 mm plates to 90% 
confluency and scrape harvested.  Cells were then fixed for 5 min in 1% freshly-made 
formaldehyde, washed with PBS, and lysed for 10 min in lysis buffer provided in the kit.  
Chromatin was sheared by sonication to an average size of ~200-500 bps, clarified, and 
precleared for 1 h at 4°C with salmon sperm DNA-saturated protein G-Sepharose beads.  
The supernatant was incubated with normal rabbit IgG, with anti-STAT3 (Santa Cruz), or 
with anti-phospho-STAT3 (Ser 727, Cell Signaling) and nutated overnight at 4°C.  
Lysates were immunoprecipitated with salmon sperm DNA-saturated protein 
G-Sepharose beads for 1 h at 4°C and washed extensively according to the manufacturer's 
instruction.  Input and immunoprecipitated protein/DNA complexes were eluted at room 
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temperature and the cross-linking was reversed overnight at 65°C in the presence of 200 
mM NaCl.  After RNase A (37°C for 30 min) and proteinase K (45°C for 2 h) treatment, 
sample DNAs were purified as directed by the manufacturer for further analysis.  PCR 
of ChIP products were performed with HotStar Taq polymerase (Qiagen) and Primer pairs 
used for different ChIP target sequences include：Bcl-3-Pro：5’ 
TGACCCGGACTCAACCCCAG 3’ and 5’ TCTCCTCCCCTCCTCTCCCTC 3’；HS3：
5’ CGCTTCCTCCAACCTTAACC 3’ and 5’ TGCCCAGTCCCTAACCTCTT 3’；HS4：
5’ CATTCGAGGATGGAAGTTGG 3’ and 5’ CAGGGTTAAGTGAGGGCAGA 3’.   
 
Quantitative Real Time Polymerase Chain Reaction (QRT-PCR) 
Total cell RNA was isolated using RNAeasy kit as directed by the manufacturer 
(Qiagen).  Primer pairs used in this paper include actin：5’ 
TCACCCACACTGTGCCCATCTACGA 3’ and 5’ 
CAGCGGAACCGCTCATTGCCAATGG 3’；EGFR：5’ CTGCGTCTCTTGCCGGAATG 
3’ and 5’ TTGGCTCACCCTCCAGAAGG 3’；Bcl-3：5’ ACAACAGCCTTAGCATGGTG 
3’ and 5’ GCTGAGTGCAGGGCGGAGCT 3’；IL-6：5’ 
AGCCACTCACCTCTTCAGAAC 3’ and 5’ GCTGCTTTCACACATGTTACTCTT 3’.  
Quantitative real time-PCR (QRT-PCR) was performed using Quantitect SYBR Green 
RT-PCR kit (Qiagen) according to the manufacturer’s instruction.  Amplification of PCR 
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products was detected using ABI 7900HT sequence detection system (Applied 
Biosystems) and analyzed using SDS 2.0 software (Applied Biosystems).  The cycle 
threshold (CT) was determined as the number of PCR cycles required for a given reaction 
to reach an arbitrary fluorescence value within the linear amplification range.  The 
change in CT (∆CT) was determined between the same target gene primer sets and 
different samples, and the change in ∆CT (∆∆CT) was determined by adjusting for the 
difference in the number of cycles required for actin to reach the CT.  The fold change 
was determined as 2∆∆CT since each PCR cycle results in a twofold amplification of each 
PCR product.  Quantitative real time-PCR was also performed to amplify ChIP products 
and primer pairs used for different ChIP target sequences include：Bcl-3-Pro：5’ 
TGACCCGGACTCAACCCCAG 3’ and 5’ TCTCCTCCCCTCCTCTCCCTC 3’；HS3：
5’ CGCTTCCTCCAACCTTAACC 3’ and 5’ AAGAGGAGCCGGTGGCGCAG 3’；
HS4：5’ TTACTGGAAGTCCGAGGGCT 3’ and 5’ TTCAGAGAAACCGTCCAGGC 3’. 
 
RESULTS 
CTAR1 of LMP1 induces EGFR mRNA and protein.  The CTAR1 domain of 
LMP1 has previously been shown to induce expression of the EGFR.  The full length 
LMP1, 1-231 (contains only CTAR1 but not CTAR2), and d187-351 (contains only 
CTAR2 but not CTAR1) previously cloned into the pBabe retroviral expression vector 
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were stably transduced into C33A epithelial cells (Fig. 1B) (17).  Expression of LMP1 
and the CTAR deletion mutants and EGFR expression was evaluated by immunoblotting 
(Fig. 1A).  As previously shown, LMP1 and CTAR1 but not CTAR2 of LMP1 induced 
EGFR expression with highly elevated levels induced by CTAR1 (43).  In addition, high 
levels of phosphorylated, activated EGFR were detected using a phospho-specific 
antibody, indicating that the EGFR induced by CTAR1 is functionally active.  Real-time 
quantitative reverse transcription PCR (QT-PCR) confirmed previous studies that 
indicated that LMP1 upregulates EGFR at the mRNA level (42) (Fig. 1C).  
Quantification of the immunoblot indicated that in C33A cells LMP1 and CTAR1 induced 
EGFR mRNA expression 7-fold and 17-fold, respectively.  LMP1-CTAR2 did not affect 
EGFR mRNA level or the levels of phosphorylated EGFR protein.  Although the levels 
of LMP1 expression were very similar, the total and activated EGFR induced by 
LMP1-CTAR1 was significantly higher than full-length LMP1.  This suggests that 
CTAR2 or sequences between CTAR1 and CTAR2 may inhibit the ability of CTAR1 to 
induce specific targets, such as EGFR. 
LMP1-CTAR1 upregulates Bcl-3 expression and induces nuclear 
translocation of Bcl-3 and p50.  In studies of EBV-positive NPC xenografts, p50 and 
Bcl-3 were detected by chromatin immunoprecipitation (ChIP) to be bound to the EGFR 
promoter while other forms of NF-kB were not detected (58).  In addition, in C33A cells, 
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transient overexpression of Bcl-3 and/or p50 slightly increased EGFR expression and 
p50/Bcl-3 complexes could be detected by CHIP on the EGFR promoter in C33A cells 
expressing LMP1-CTAR1 (59).  To determine the effect of LMP1 and LMP1-CTAR1 on 
the localization and expression levels of Bcl-3 and p50, lysates of whole cell and nuclear 
fractions were analyzed by western blotting.  Both LMP1 and LMP1-CTAR1 increased 
levels of Bcl-3 in the whole cell lysates, approximately 2.1-fold and 4.6-fold respectively 
(Fig. 2A).  Elevated levels of p50 and Bcl-3 were also detected in the nucleus of the 
LMP1-expressing C33A cells (Fig. 2B).  Equal loading was confirmed by 
Fig. 1.  CTAR1 of LMP1 upregulates EGFR mRNA levels.  A) LMP1 and EGFR 
expression was examined by western blot analysis in C33A cells expressing HA-tagged 
LMP1, deletion mutant 1-231, and deletion mutant d187-351.  B) A schematic of 
LMP1, 1-231, and d187-351 constructs.  C) Expression of EGFR mRNA in stable 
C33A cells was analyzed by quantitative RT-PCR.  Fold change was normalized to 
actin.  Data shown are the mean values of three independent experiments, each being 
performed in triplicate. 
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immunoblotting for the cytosolic and nuclear proteins, GRP78 and PARP.  
Quantification using the ImageJ software and normalization to the intensity of PARP 
bands indicated that LMP1-expressing C33A cells had a 1.4–fold increase of nuclear 
Bcl-3 and LMP1-CTAR1 expressing cells had an approximately 1.9–fold increase.   
 
            
 
 
 
 
Fig. 2.  CTAR1 of LMP1 upregulates Bcl-3 and induces nuclear translocation of 
Bcl-3 and p50.  A) Bcl-3 expression in stable C33A cells was examined by western 
blotting and quantitated using ImageJ software.  Data shown are the mean values of 
three independent experiments.  B) Nuclear p50 and Bcl-3 in C33A stable cells were 
shown by western blotting and quantitated using ImageJ software.  Data shown are the 
mean values of four and three independent experiments for Bcl-3 and p50, respectively.  
Fold change was normalized to GRP78 and PARP in A) and B), respectively.  C) 
mRNA of Bcl-3 was examined by quantitative RT-PCR.  Fold change was normalized 
to actin.  Data shown are the mean values of three independent experiments, each being 
performed in triplicate. 
 
94 
 
LMP1-CTAR2 did not affect the levels of whole cell or nuclear Bcl-3 compared to vector 
control cells.  Expression of LMP1 or LMP1-CTAR1 also significantly induced the               
nuclear translocation of NF-κB p50, approximately 13- and 16-fold, respectively (Fig. 2B) 
(48).  Although LMP1-CTAR2 induces greater levels of NF-κB activity in reporter 
assays, in C33A cells expressing LMP1-CTAR2 nuclear p50 was only increased 5-fold 
(25, 57).  QT-PCR using Bcl-3 specific primers indicated that Bcl-3 mRNA was 
increased approximately 1.9–fold and 3.3–fold inductions in LMP1- and LMP1-CTAR1 
expressing cells (Fig. 2C).  LMP1-CTAR2 did not affect the Bcl-3 mRNA level.  These 
results indicate that LMP1-CTAR1 not only induces the nuclear translocation of NF-κB 
Bcl-3 and p50, it also transcriptionally activates Bcl-3. 
STAT3 is constitutively activated by LMP1-CTAR1.  Previous studies have 
shown that LMP1 can activate signal transducer and activator of transcription 3 (STAT3) 
and that the activated STAT3 may regulate LMP1 expression through effects on the novel 
LMP1 promoter within the terminal repeats that is active in NPC (9, 10, 32, 52).  STAT3 
has also been shown to transcriptionally activate Bcl-3 through enhancer sequences 
detected within the Bcl-3 introns (4).  The transcriptional activity of STAT3 is regulated 
by phosphorylation.  Phosphorylation at tyrosine 705 induces STAT3 dimerization while 
phosphorylation at serine 727 affects DNA binding and transcriptional activity (3, 13).  
To determine the effects of LMP1 and LMP-1 on STAT3 activation, serine and tyrosine 
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phosphorylated STAT3 was identified using phospho-specific STAT3 antibodies, 
quantified by ImageJ, and normalized to loading control, GRP78 (Fig. 3A).  The fold 
induction is indicated beneath the corresponding bands of a representative experiment out 
of three independent attempts.  Cells expressing LMP1 had an approximately 2.4-fold  
 
        
 
 
 
 
 
Fig. 3.  CTAR1 of LMP1 upregulates Bcl-3 and EGFR by activating STAT3.  A) 
Total and phosphorylation levels of STAT3 were examined by western blotting.  Fold 
inductions are listed beneath their corresponding bands.  The blot is representative of 
three independent experiments.  B) Phosphorylation of STAT3, as well as expression of 
Bcl-3 and EGFR, was examined in 1-231-expressing C33A cells treated with the 
STAT3-specific inhibitor, Cucurbitacin.  C) mRNA of EGFR was examined by 
quantitative RT-PCR in pBabe control, 1-231 cells treated with DMSO, and 1-231 cells 
treated with Cucurbitacin.  Fold change was normalized to actin.  Data shown are the 
mean values of four independent experiments, each being performed in triplicate. 
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increase in tyrosine-phosphorylated STAT3 and 2.5-fold increase in 
serine-phosphorylated STAT3 compared to vector control.  Cells expressing 
LMP1-CTAR1 had an approximately 3-fold increase in tyrosine-phosphorylated STAT3 
and 4-fold increase in serine-phosphorylated STAT3.  LMP1-CTAR2 had an 
approximately 1.6-fold increase in tyrosine-phosphorylated STAT3 and 1.7-fold increase 
in serine-phosphorylated STAT3.  Although the levels of phosphorylated STAT3 were 
increased by LMP1, the total level of STAT3 was not affected.  Cucurbitacin is a specific 
inhibitor of STAT3 activation through effects on the Janus kinases (2, 31).  Treatment of 
the LMP1-CTAR1 expressing C33A cells with Cucurbitacin reduced both the tyrosine 
and serine phosphorylation of STAT3 induced by LMP1-CTAR1 (Fig. 3B).  The effects 
of Cucurbitacin were dose-dependent in that 1μM of Cucurbitacin reduced 
LMP1-CTAR1-mediated induction to the level detected in control cells while 10μM 
eliminated phosphorylated STAT3.  Importantly, treatment with Cucurbitacin 
significantly reduced the effects of LMP1-CTAR1 on Bcl-3 and EGFR and at 10μM 
expression of Bcl-3 was eliminated.  QT-PCR of EGFR mRNA indicated that EGFR 
mRNA was reduced 63% and 86% by 1μM and 10μM of Cucurbitacin (Fig. 3C).  These 
results suggest that CTAR1-mediated STAT3 activation is required for Bcl-3 induction 
and at least partially responsible for the induction of EGFR.  Previous studies have 
shown that LMP1 can induce expression of IL-6 resulting in activation of STAT3 (4, 9, 10, 
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16).  To determine whether LMP1-mediated STAT3 activation resulted from IL-6 
induction in C33A cells, QRT-PCR was performed to detect IL-6 mRNA (Fig. 4).  In 
C33A cells, IL-6 mRNA level was induced by LMP1, LMP1-CTAR1, or LMP1-CTAR2 
to 1.6-, 2.7-, and 4.2-fold, respectively.  The highest induction was detected in 
LMP1-CTAR2 cells that didn’t activate STAT3.  These data indicate that STAT3 is 
constitutively activated by LMP1-CTAR1 in C33A cells through mechanisms that are not 
dependent on IL-6 induction. 
      
     
 
 
LMP1 CTAR1 induces STAT3 binding to sites in the Bcl-3 promoter and 
introns.  Two enhancers, HS3 and HS4, have been identified within introns of Bcl-3 that 
mediate STAT3 induction of Bcl-3 (4).  HS3 contains one and HS4 has three putative 
Fig. 4.  IL-6 production in C33A cells.  Expression level of IL-6 mRNA in stable 
C33A cells was analyzed by quantitative RT-PCR.  Fold change was normalized to actin.  
Data shown are the mean values of four independent experiments, each being performed 
in triplicate. 
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STAT3 binding sites, respectively (Fig. 5A).  The online program, ALGGEN-PROMO, 
(http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promo.cgi?dirDB=TF_8.3&calledBy=a
lggen) was also used to predict STAT3 binding sites in the Bcl-3 promoter.  One 
potential site (Bcl-3-Pro) was identified at approximately 1200 bps upstream of the Bcl-3 
transcriptional start site (Fig. 5A) (18, 39).  To determine if LMP1-CTAR1 induces 
binding of STAT3 to these putative binding sites, ChIP analysis was performed in C33A 
cells stably expressing pBabe vector control and LMP1-CTAR1 using primers specific for 
each of the three predicted sites (Fig. 5B).  In the pBabe control cells, precipitation with 
STAT3 or serine-phosphorylated-STAT3 antibodies did not increase the amplification 
compared to precipitation with normal rabbit immunoglobulin.  In LMP1-CTAR1 cells, 
precipitation with STAT3 antibody slightly increased amplification of all three putative 
STAT3 binding sites.  However, precipitation with the serine-phosphorylated specific 
STAT3 antibody detected increased binding between STAT3 and all three putative STAT3 
binding sites in the presence of LMP1-CTAR1.  LMP1-CTAR1 did not increase 
interaction between STAT3 and a nonspecific target within EGFR Exon2, indicating the 
specificity of the effect (data not shown).  This result was confirmed using quantitative 
PCR to amplify ChIP products and the data were normalized to determine the enrichment 
fold in LMP1-CTAR1 cells compared to pBabe control cells (Fig. 5C).  In 
LMP1-CTAR1 cells, the binding of serine phosphorylated STAT3 to Bcl-3-Pro, H3, and 
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H4 was increased 4.2-, 3-, and 4.6-fold, respectively.  These data indicate that LMP1 
CTAR1 likely regulates Bcl-3 by increasing the interaction of serine phosphorylated 
STAT3 to multiple binding sites that regulate Bcl-3 expression. 
 
              
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.  LMP1 CTAR1 induces binding of STAT3 to Bcl-3 promoter and intronic 
enhancers.  A) Schematic representation of putative STAT binding sites.  HS3 and 
HS4 were suggested in Brocke-Heidrich K et al. paper.  Bcl-3-Pro was predicted using 
ALGGEN-PROMO online program.  B) Chromatin immunoprecipitation（ChIP）
analysis using normal IgG（lane 2）, STAT3（lane 3）, and Serine-phosphorylation-STAT3
（lane 4）antibodies in pBabe control and CTAR1-expressing C33A cells.  Precipitated 
complexes were subjected to PCR with primer pairs specific to Bcl-3-Pro, HS3, and HS4 
regions.  PCR was also performed with chromatin input（lane 1）.  C) Quantitative real 
time-PCR was performed to amplify ChIP products from pBabe control and 
CTAR1-expressing cells.  Enrichment fold was calculated by normalizing results from 
CTAR1 cells to pBabe cells.  Data shown are the mean values of two independent 
experiments, each being performed in triplicate. 
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DISCUSSION 
The induction of EGFR expression by LMP1 is likely a contributing factor to the 
development of cancer.  The EGFR is frequently expressed at high levels in a variety of 
human cancers, including NPC (40, 54, 69).  Stimulation of the tyrosine kinase activity 
of EGFR affects multiple signaling pathways leading to deregulation of cellular growth 
control and tumorigenesis (5, 65).  Thus the effect of LMP1 on EGFR expression is 
likely an important factor in carcinogenesis.  The unique activation of EGFR expression 
by LMP1-CTAR1 provides a novel system to assess the contribution of NF-kB activation.  
It was initially thought that p50/p50 or p52/p52 homodimers were transcriptionally 
inactive as these forms of NF-kB lack transactivation domains.  However, subsequent 
studies determined that Bcl-3, which contains a transcriptional transactivation domain, 
can convert these complexes into active forms (19, 46, 47).  It is thought that one of the 
major functions of Bcl-3 is to bring p50 into the nucleus and the increased nuclear 
presence of p50 correlates with elevated Bcl-3 in LMP1 CTAR1-expressing cells (61, 68).   
It has also been suggested that Bcl-3 might contribute to p50 activation by inhibiting the 
ubiquitination and subsequent degradation of DNA-bound p50 homodimers (7).  The 
data presented here indicate that Bcl-3 is also regulated by LMP1-CTAR1 resulting in 
increased Bcl-3 mRNA, protein, and nuclear translocation of Bcl-3.  The data also 
indicate that the effects of LMP1 on Bcl-3 are linked to its effects on STAT3.  STAT3 is 
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known to be activated in EBV-infected and LMP1-expressing epithelial cells and B-cell 
lymphomas (6, 9, 10, 32, 55).  The induction of IL-6 by LMP1 can result in activation of 
STAT3 and increased IL-6 production has been detected in EBV-infected and 
LMP1-expressing epithelial cells (9, 10).  In multiple myeloma cells, Bcl-3 transcription 
has been shown to be induced by IL-6 via STAT3 binding to intronic enhancers (4).  
However as shown here, IL-6 transcription was slightly induced in LMP1- and 
CTAR1-expressing C33A cells but was induced the highest in CTAR2-expressing cells, 
where no EGFR or Bcl-3 induction was detected.  In addition, treatment with 
recombinant IL-6 did not increase serine phosphorylation of STAT3 or EGFR expression 
in pBabe control or CTAR1-expressing cells (data not shown).  These data indicate that 
LMP1 CTAR1 mediates constitutive activation of STAT3 independently of effects on 
IL-6.  IL-6-independent STAT3 activation by EBV has been suggested in studies where 
retinoic acid treatment of EBV-immortalized B lymphocytes inhibited IL-6-dependent but 
not constitutive STAT3 activation (67).   
It is not yet clear what exact signaling pathways activate STAT3 in 
LMP1-expressing cells.  It was previously suggested that a novel activating region 
between CTAR1 and CTAR2 of LMP1 interacts with Janus kinase 3 (JAK3) and activates 
JAK/STAT signaling pathway (22).  However, in EBV-transformed lymphoblastoid cell 
lines, the putative activating region did not mediate JAK3 association or JAK/STAT3 
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activation (23).  In addition, in data presented here LMP1-CTAR1 is a deletion mutant, 
containing aa 1-231, that lacks this domain yet activates STAT3 considerably more 
effectively than full-length LMP1 (Fig. 3).  These data indicate that the putative 
JAK-binding domain is not important for LMP1-mediated STAT3 activation in C33A 
cells.  However, the inhibition of this activation by Cucurbitacin which is thought to 
inactivate STAT3 through inhibiting JAK2 and JAK3 activity may indicate that regulation 
of JAK activity contributes to LMP1-mediated STAT3 activation (2, 56).  It will be of 
interest to determine how the CTAR1/TRAF complexes possibly affect STAT3 activity or 
the Janus kinases.   
Several signaling pathways affected by LMP1 have been associated with STAT3 
activation.  Serine phosphorylation of STAT3 has been shown to be mediated by 
PI3K/AKT and ERK signaling pathways which are both activated by LMP1-CTAR1 (11, 
20, 34, 35, 50, 62).  Interestingly, EGFR also activates STAT3 which suggests a positive 
signaling loop of  STAT3→Bcl-3→EGFR→STAT3 may be established in 
LMP1-expressing cells and during EBV-mediated transformation (8, 49). 
A recent study suggested that LMP1 induces Bcl-3 expression through CTAR2 
and NF-κB pathway (45).  This study showed that deletion of CTAR2 or the NF-κB 
binding sites in the Bcl-3 promoter abolished activity of a Bcl-3 reporter construct in 
LMP1-expressing Jurkat cells.  The difference between this study and the data presented 
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here may reflect that the construct used in that study contained amino acid 1-331 of 
LMP1 protein, which is 100 amino acids longer than the CTAR1 construct (1-231) tested 
in our study.  This region of aa 231-331 of LMP1 may have an inhibitory effect on 
CTAR1-mediated Bcl-3 induction.  Possible inhibition by this domain is also suggested 
by the fact that CTAR1 alone has higher activity of inducing Bcl-3 and EGFR than 
full-length LMP1 (Fig. 1 and Fig. 2).  Importantly, the LMP1-CTAR2 deletion mutant 
was only tested using a Bcl-3 reporter construct and CTAR1 was not tested for its effects 
on Bcl-3 expression in cell lines.  In addition, the reporter construct did not include the 
STAT3-binding site located approximately 1200 bps upstream of Bcl-3 transcriptional 
start site which had the strongest interaction with STAT3 and serine phosphorylated 
STAT3 in CTAR1-expressing C33A cells.  This STAT3 binding site is likely important 
for CTAR1-mediated Bcl-3 induction.   
It is intriguing that CTAR1 had a considerably stronger effect than full length 
LMP1 although both were expressed at very similar levels.  It is possible that the 
presence of CTAR2 downregulates the ability of CTAR1 to induce Bcl-3 and EGFR.  
LMP1 CTAR2 mediates downstream signaling pathways through TRAF2 or TRAF6 
which both are potential E3 ubiquitin ligases (26, 63).  Since it has been shown that both 
EGFR and Bcl-3 can be regulated by ubiquitination, it is possible that either 
CTAR2-recruited TRAF2 or TRAF6 affects LMP1-mediated induction of EGFR and 
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Bcl-3 (24, 29, 30, 36, 60).   
In summary, the data here suggest a model of LMP1-mediated induction of EGFR 
with constitutive activation of STAT3 by CTAR1 through induction of tyrosine and serine 
phosphorylation of STAT3 (Fig. 6).  The serine phosphorylated STAT3 would increase 
Bcl-3 expression through interaction with multiple STAT-binding sites in both the 
promoter and introns of Bcl-3.  The increased levels of Bcl-3 and the elevated levels of 
p50 form a transcriptional active complex to transactivate EGFR.  The link between  
 
 
 
 
 
Fig. 6.  A working model for LMP1 CTAR1-mediated induction of Bcl-3 and, 
consequently, EGFR.   
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STAT3 and EGFR has also been shown by microarray data of epithelial cells 
overexpressing STAT3 (64).  It has been suggested that the unique activation of distinct 
genes by LMP1-CTAR1 reflects its activation of the noncanonical pathway (33).  
However, the data presented here reveal that LMP1-CTAR1 has an additional mechanism 
to activate NF-kB through its effects on STAT3 and Bcl-3.  As multiple genes have been 
shown to be regulated by the Bcl-3/p50-homodimer complex, it is likely that this pathway 
is responsible for other genes induced by LMP1 in EBV-associated tumorigenesis. 
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ABSTRACT 
Epstein-Barr Virus (EBV) latent membrane protein 1 (LMP1) is required for EBV  B-
lymphocyte transformation, transforms rodent fibroblasts, and can induce lymphoma and 
epithelial hyperplasia in transgenic mice.  Two domains have been identified within the 
intracellular carboxy-terminus that can activate NF-kB, CTAR1 and CTAR2, through 
interactions with tumor necrosis receptor associated factors (TRAFs).  CTAR1 can activate 
both the canonical and noncanonical NF-κB pathways and has unique effects on cellular gene 
expression.  The epidermal growth factor receptor is highly induced by LMP1-CTAR1 in 
epithelial cells through activation of a novel NF-κB form containing p50 homodimers and 
Bcl-3.  To further understand the regulation of NF-κB in CTAR1-induced EGFR expression, 
we evaluated the ability of CTAR1 to induce EGFR in mouse embryonic fibroblasts (MEFs) 
defective for different NF-κB effectors.  CTAR1-mediated EGFR induction required the NF-
κB Inducing Kinase (NIK) but not the IKK complex components that regulate canonical or 
noncanonical NF-κB pathways.  CTAR1-induction of nuclear p50 occurred in IKKβ-, IKKγ-, 
and NIK-defective MEFs, indicating that this form is not dependent on the canonical or 
noncanonical NF-κB pathways.  The CTAR1-induction of p50 was proteasome-dependent.  
EGFR and nuclear p50 were expressed at high levels in TRAF2- fibroblasts and were not 
induced by LMP1.  EGFR was low in TRAF3- fibroblasts and was not induced by LMP1 
while in TRAF6- MEFs, EGFR was not expressed but was induced by LMP1-CTAR1.   
These findings suggest that endogenous EGFR regulation is independent of TRAF2 and that 
the effects of LMP1-CTAR1 require TRAF3 but are independent of TRAF6.    Importantly, 
this novel NFkB pathway is differentially regulated by TRAF2 and TRAF3.   
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INTRODUCTION 
The Epstein-Barr virus is a human gammaherpesvirus that infects more than 95% of 
the world population and is associated with multiple malignancies, including Hodgkin’s 
disease (HD), NK or T-cell lymphoma, Burkitt’s lymphoma (BL), post-tranplant 
lymphoproliferative disease (PTLD), gastric carcinoma (GAC), and nasopharyngeal 
carcinoma (NPC) (44).  Latent membrane protein 1 (LMP1) is considered the EBV oncogene 
and is essential for EBV-mediated B-cell transformation (21).  Moreover, LMP1 can 
transform rodent fibroblast cells and LMP1-transgenic mice develop B-cell lymphoma and 
epithelial hyperplasia (24, 33, 55, 56).  LMP1 is expressed in multiple EBV-associated 
malignancies and acts as a constitutively active tumor necrosis factor receptor (TNFR) by 
recruiting TNFR-associated factors (TRAFs) to the cell membrane (22, 51).  Numerous 
cellular genes have been shown to be induced by LMP1, including ICAM-1, TRAF1, A20, 
Id1, Id3, Bcl-2, Bcl-3, and EGFR (25, 26, 37, 46, 50).  LMP1 has two major signaling 
domains, c-terminal activating region (CTAR) 1 and 2, that bind different TRAFs and 
activate distinct signaling pathways.  CTAR1 recruits TRAF1, 2, 3, and 5, and uniquely 
activates noncanonical NFkB, phosphatidylinositol 3-kinase (PI3K)-Akt, and the MAPK 
pathways.  CTAR2 recruits TRAF2 and TRAF6 through adaptors TRADD and BS69 to 
activate canonical NFkB and c-Jun N-terminal kinase (JNK) signaling pathway (8, 33, 34, 
51). (19, 43).  CTAR1 is required LMP1-mediated fibroblast transformation and for B-
lymphocyte transformation while CTAR2 is dispensable (19, 33, 34, 43).   
The nuclear factor-κB (NF-κB) is a transcription-factor family that dimerize and bind 
to κB sites within the promoter/enhancers to regulate transcription of genes that impact a 
variety of biological processes, including cell cycle progression, apoptosis, differentiation, 
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inflammation , angiogenesis, and cell proliferation (16, 35).  The NF-κB family consists of 
five members, p50, p52, p65 (RelA), RelB, and c-Rel, all of which share a Rel homology 
domain responsible for dimerization and DNA binding.  The transcription activation domain 
required for gene regulation only exists in p65, RelB, and c-Rel.  The activation of NF-κB is 
tightly regulated through interactions with inhibitors of NF-κB (IκBs), which include p105 
(precursor of p50), p100 (precursor of p52), IκBα, IκBβ, IκBγ, IκBε, IκBζ, and Bcl-3.  IκBs 
mainly function by sequestering inactive NF-κB dimers in the cytoplasm to prevent their 
activity.  Upon receiving an extracellular stimulus, such as binding of TNFα to its receptor, 
activation of a kinase cascade that includes IκB kinase alpha (IKKα), IKKβ, and IKKγ 
(NEMO) results in the phosphorylation of IκBs and leads to their ubiquitination and 
degradation.  NF-κB members are then released into the nucleus for transcriptional 
regulation.  In the canonical NF-κB pathway, an IKK complex consisting of 
IKKα/IKKβ/IKKγ is activated and results in IKKα/IKKβ-mediated phosphorylation and 
degradation of IκBα.  Degradation of IκBα releases multiple NF-κB dimers, primarily 
p50/p65 into the nucleus.  In the noncanonical NF-κB pathway, NF-κB inducing kinase 
(NIK) phosphorylates and activates IKKα in a IKKβ/γ-independent manner.  Activated IKKα 
phosphorylates p100 and triggers proteasome-mediated processing of p100 to p52, liberating 
p52-containing NF-κB dimers, such as p52:RelB into the nucleus.  Due to the very different 
mechanisms of activation, canonical and noncanonical NF-κB pathways regulate distinctive 
transcriptional regulation of target genes.  In addition to participating in both NF-κB 
pathways, IKKs/NIK have also been reported to phosphorylate many other proteins besides 
the IκBs.  For example, IKKα and IKKβ can both directly phosphorylate p65 (42).  IKKα has 
also been implicated in the phosphorylation of several nuclear substrates, including SMRT, 
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histone H3, and CBP (17, 18, 58).  NIK was recently suggested to function as serine kinase 
of STAT3 (40).  Aberrant regulation of NF-κB pathways has been implicated in development 
of many human cancers (35, 45). 
Initial studies characterizing LMP1 activation of NFkB showed that although CTAR2 
had greater NF-κB activation as determined using reporter assays, CTAR1 induced more 
complex NF-κB detected by EMSA (20, 36, 52).  Subsequent studies revealed that CTAR2 
only activates the canonical NF-κB pathway, whereas CTAR1 can activate both the 
canonical and noncanonical pathways (1, 9, 31, 47).  LMP-CTAR1 can transcriptionally 
activate EGFR expression and this ability was shown to be mediated through a unique NF-κB 
complex containing p50 homodimers and Bcl-3 (25, 37, 53).  The induction of this 
transcription complex requires activation of STAT3 by CTAR-1 to increase Bcl-3 
expression.  Although considered a member of the IkB family, Bcl-3 contains a 
transactivating domain and can bind to p50 and p52 homodimers to induce their 
transcriptional activating potential  (4, 14).   
To determine if NFkB-regulated EGFR expression was a result of canonical or 
noncanonical NF-κB, the effects of LMP1-CTAR1 were analyzed in genetically engineered 
mouse embryonic fibroblasts (MEFs).  LMP1-CTAR1 upregulated EGFR was independent 
of canonical or noncanonical regulation as it did not require IKKα, IKKβ, or IKKχ, but was 
dependent on NIK.  In addition, TRAF2 and TRAF3, but not TRAF6, were required for 
LMP1-CTAR1-mediated induction of EGFR in MEF cells.  These data indicate that in 
addition to canonical and noncanonical NF-κB pathways, LMP1 manipulates unique NF-κB 
complexes through CTAR1 to regulate target gene expressions. 
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MATERIALS AND METHODS 
Reagents and Cell Culture 
C33A cervical carcinoma cells were cultured in Dulbecco’s modified Eagle’s medium 
(Gibco) supplemented with 10% fetal bovine serum (Sigma) and antibiotic/antimycotic 
(Gibco) at 37°C with 5% CO2.  Wild-type, IKKα-/-, IKKβ-/-, IKKγ-/-, NIKaly/aly, TRAF2-/-, 
and TRAF6-/- mouse embryonic fibroblast (MEF) cells were kindly provided by Elliot Kieff 
(Harvard university, Boston) and were immortalized by infecting with a human papilloma 
virus 16 E6/E7 retrovirus to make MEF cells susceptible for transfection or transduction (7, 
27, 30-32, 48).  TRAF3-/- MEF cells were obtained from Michael Karin (University of 
California at San Diego) and were spontaneously immortalized by continuous passaging (15).  
Immortalized MEF cells were maintained in Dulbecco’s modified Eagle’s medium (Gibco) 
supplemented with 10% fetal bovine serum (Sigma) and antibiotic/antimycotic (Gibco) at 
37°C with 5% CO2.  To inhibit proteasome activity, 1 to 10μM of MG132 (26S inhibitor) or 
clasto-Lactacystin β-Lactone (20S inhibitor) (Calbiochem) was added to ~90% confluent 
cells for 5 hours before preparing cell lysates. 
 
Plasmids 
Generation of plasmid constructs expressing both myc-tagged (pCDNA3) and HA-
tagged (pBabe) full-length LMP1, LMP1-CTAR1 (which contains aa 1-231 of LMP1), and 
LMP1-CTAR2 (which has aa 187-351 of LMP1 deleted) was described previously (11).  
Myc-tagged and HA-tagged LMP1 constructs contain neomycin- and puromycin-resistant 
cassette, respectively.  HA-tagged LMP1, LMP1-CTAR1, and LMP1-CTAR2 were also 
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subcloned into pCDNA3 vector with zeocin-resistant cassette by digesting pBabe-LMP1 / 
CTAR1 / CTAR2 with BamHI / EcoRI and ligated to BamHI / EcoRI-digested pCDNA3.1-
zeocin vector (Invitrogen).  Wild-type and dominant-negative NIK constructs were kindly 
provided by Christian Jobin (University of North Carolina at Chapel Hill) and Elliot Kieff 
(Harvard University). 
 
Retrovirus production and transduction 
Recombinant retrovirus production and transduction were performed as previously 
described to transduce full-length LMP1, CTAR1 (1-231), CTAR2 (d187-351), or pBabe 
vector control (25).  Briefly, ~60-80% confluent 293T cells in 100mm plates were triply 
transfected using FuGEGE6 transfection reagent (Roche) according to the manufacturer’s 
instruction with 5µg pBabe (vector), pBabe-HA-LMP1, pBabe-HA-CTAR1, or pBabe-HA-
CTAR2, and 5µg pVSV-G and 5µg pGag/Pol expressing plasmids.  After 24 hours of 
incubation at 37°C, the culture media were replaced with fresh media and the cells were 
transferred to 33°C for another 24 hours of incubation.  Cell supernatants were centrifuged at 
1000g for 5 min to remove cell debris and virus-containing supernatant was collected and 
stored in -80°C if not immediately used.  Cells to be transduced were grown to ~70-80% of 
confluence and then transduced with virus-containing supernatant with 4µg/ml polybrene for 
24-48 hours at 37°C. 
 
Generation of stable cell lines 
C33A stable cell lines expressing CTAR1 (1-231) or vector control pBabe were 
established by retroviral transduction followed by selection and passages in the presence of 
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1µg/ml puromycin (Sigma).  IKKβ-/- and NIKaly/aly MEF cells stably expressing CTAR1 
were generated by transducing cells with pBabe- and CTAR1-containing retrovirus solution 
with 4µg/ml polybrene for 24-48 hours at 37°C, followed by selection and passages in the 
presence of 1µg/ml puromycin.  IKKα-/- and IKKγ-/- MEF cells stably expressing CTAR1 
were made by transfecting cells with myc-tagged pCDNA3 vector or pCDNA3-CTAR1 
construct using FuGEGE6 transfection reagent for 48 hours at 37°C, followed by selection 
and passages in the presence of 0.8mg/ml G418 (Mediatech).  Stable LMP1-, CTAR1-, and 
CTAR2-expressing TRAF2-/- and TRAF6 MEF cells were generated by transfecting cells 
with HA-tagged pCDNA3.1 vector, pCDNA3.1-LMP1, pCDNA3.1-CTAR1, or pCDNA3.1-
CTAR2 construct using FuGEGE6 transfection reagent for 48 hours at 37°C, followed by 
selection and passages in the presence of 400μg/ml Zeocin (Invitrogen). 
 
Fractionation of Cells 
Cells were fractionated as previously described (25).  Briefly, after cultured cells 
reached ~90% confluence, cells were scrape harvested, washed once with cold phosphate-
buffered saline (PBS, Gibco), centrifuged at 1000g for 5-10 min to get cell pellets.  Whole 
cell lysates were made by lysing cells with RIPA buffer (20mM Tris-HCl [pH 7.5] 
, 150mM NaCl, 1mM EDTA, 1% NP-40, 0.1% sodium dodecyl sulfate [SDS], 0.1% 
deoxycholic acid) supplemented with phenylmethylsulfonyl fluoride (PMSF), sodium 
orthovanadate (Na3VO4), protease and phosphatase inhibitor cocktail (Sigma).  After 
incubation at 4°C for 15min, lysates were then clarified by centrifugation at 13,000 rpm, 4°C 
for 15 min and supernatants containing whole cell lysates were transferred to new tubes.  
Nuclear extracts were made by lysing initial cell pellets in a hypotonic buffer (20 mM 
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HEPES, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA) supplemented with PMSF, Na3VO4, 
protease and phosphatase inhibitor cocktail (Sigma) for 15 min on ice.  Nonidet P-40 was 
then added to a final concentration of 1%, followed by 1 min of vortex.  Nuclei were pelleted 
by low-speed centrifugation at 2,000 rpm for 10 min at 4°C and the supernatant were 
collected as cytoplasmic fraction.  The nuclei fraction was purified using the Optiprep 
reagent (Sigma) as directed by the manufacturer.  Nuclei were lysed with nuclear extraction 
buffer (20 mM Tris-HCl [pH 8.0], 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 25% 
glycerol, PMSF, Na3VO4, protease and phosphatase inhibitor cocktail [Sigma]) with the salt 
concentration adjusted to 400 mM with 5 M NaCl.  All lysates were stored at -80°C. 
 
Western Blot Analysis 
Protein concentration of cell lysates was determined using Bio-Rad DC protein assay 
system according to manufacturer’s instruction.  Equal amounts of protein were used for 
SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to Optitran (Schleicher 
and Schuell) for Western blot analysis.  Primary antibodies used include anti-p50 (Abcam), 
anti-p65 (RelA), anti-NIK, anti-RelB, anti-GAPDH, anti-GRP78, anti-PARP (Santa Cruz), 
anti-phospho-STAT3 (Ser 727 and Tyr 705) (Cell Signaling), anti-phospho-EGFR (Tyr 
1068), anti-β-catenin (BD Biosciences), and anti-HA tag (Covance).  A rabbit antiserum 
raised against the carboxyl-terminal 100 amino acids of the EGFR fused to glutathione S-
transferase was kindly provided by H. Shelton Earp (University of North Carolina at Chapel 
Hill) and used to detect total EGFR expression.  Secondary antibodies used to detect bound 
proteins include horseradish peroxidase-conjugated antimouse, antirabbit (Amersham 
Pharmacia), and antigoat (DAKO).  After treatment with secondary antibodies, blots were 
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developed using Pierce Supersignal West Pico chemiluminescence system followed by 
exposure to film (ISCBioexpress). 
 
RESULTS 
LMP1 Effects on EGFR expression in mouse embryonic fibroblast cells.  To 
assess the induction of EGFR expression by LMP1 in mouse embryonic fibroblast (MEF) 
cells, full length LMP1, LMP1-CTAR1, and LMP1-CTAR2 were expressed using the pBabe 
retroviral vector and transduced into wild-type MEF cells (11).  The expression of LMP1 and 
deletion mutants and EGFR was determined by immunoblotting (Figure 1).  EGFR was  
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Fig 1.  EBV LMP1-CTAR1 mediates mild induction of EGFR expression in mouse 
embryonic fibroblast (MEF) cells.  Control vector pBabe, full length LMP1, truncated 
LMP1 containing only CTAR1, or truncated LMP1 containing only CTAR2 were 
transduced into wild-type MEF cells.  Expression of EGFR and LMP1 derivatives were 
analyzed by immunoblotting with EGFR and HA-tag antibodies.  Expression of GRP78 
was measured by immunoblotting as loading control. 
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readily detected in the wt MEFs, and both LMP1 and LMP1-CTAR1 increased EGFR 
expression while LMP1-CTAR2 alone did not affect it (25, 53).  The induction of EGFR by 
LMP1 was less in the MEF cells than was previously shown in the C33A cells, a difference 
that likely reflects the higher basal levels of expression in the MEFs.  
CTAR1-mediated EGFR upregulation is NIK-dependent, but NIK is not 
sufficient to mimic LMP1-mediated EGFR induction.  CTAR1 of LMP1 activates both 
the canonical and noncanonical NF-κB pathways to activate distinct NF-κB complexes, 
including p50/65, p52/p50, p52/RelB, and p50/50 (36, 43).  The activation of canonical or 
noncanonical NFkB is linked to complexes that contain different members of the inhibitor of 
NF-κB kinase kinases (IKK).  The canonical pathway requires IKKα, IKKβ and in some 
instances, IKKγ, while the noncanonical pathway requires the activation of IKKα resulting 
from phosphorylation by the NF-κB inducing kinase, NIK.  The effects of expression of 
LMP1 or CTAR1 on EGFR and serine and tyrosine phosphorylation of STAT3 were 
evaluated in MEF cells lacking these regulators of NF-κB pathway (Figure 2).  The MEFS 
had differing levels of endogenous EGFR, however, LMP1 or LMP1-CTAR1 induced EGFR 
protein in IKKα-, IKKβ-, and IKKγ-defective MEF cells.  As these IKKs are required for 
activation of the canonical NF-κB pathway, these data indicate that LMP1-mediated EGFR 
upregulation is not dependent on the canonical NF-κB pathway.  Moreover, since IKKα is 
the critical regulator in the noncanonical NF-κB pathway, the result also reveals that the 
noncanonical NF-κB pathway is not required for LMP1-mediated EGFR induction.  
Interestingly, EGFR expression was not induced by CTAR1 in NIK-defective MEF cells.  
These results suggest that LMP1 induces EGFR through an IKKα-independent but NIK-
specific pathway. 
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Expression of LMP1 increased serine phosphorylation of STAT3 in wild-type MEF 
cells, IKKα, and IKKγ-defective MEF cells, but not in IKKβ or NIK null mice both of which 
had high basal levels.  Elevated tyrosine phosphorylation was detected in wild-type, IKKγ- 
and NIK-defective cells, but not in IKKα- or IKKβ-defective MEF cells.   Importantly, the 
effects of LMP1 on EGFR and STAT3 were not linked to the canonical or noncanonical NF-
κB pathways but were linked to the presence of NIK.  
A previous study showed that NIK could function as a serine kinase of STAT3 
although the high basal levels of serine phosphorylated STAT3 in NIK null cells indicate that 
Fig 2.  LMP1-mediated EGFR upregulation is NIK-dependent.  Full-length LMP1 or 
CTAR1 were transduced into wild-type MEF cells or MEF cells defective for IKKα, IKKβ, 
IKKγ, or NIK.  Expressions of LMP1 or CTAR1 were confirmed by immunoblotting with 
specific antibody against HA-tag or Myc-tag.  Expression levels of EGFR, serine-
phosphorylated STAT3, or tyrosine-phosphorylated STAT3 were analyzed by 
immunoblotting.  Expression of GRP78 was measured by immunoblotting as loading 
control.  V: vector control; L1: LMP1; C1: CTAR1. 
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other kinases can clearly phosphorylate STAT3 (40).  To confirm the requirement for NIK in 
LMP1-induced EGFR expression, CTAR1-expressing C33A cells were transiently 
transfected with dominant-negative NIK construct (DNNIK), DNNIK with aly-mutation 
(G860R; DNNIKaly), or kinase-dead NIK (NIK(K-A)) for 48 hours and the expression levels 
of EGFR and serine-phosphorylated STAT3 were analyzed by immunoblotting (Figure 3A).  
DNNIK and DNNIKaly express the c-terminus of NIK without the kinase domain.  NIK (K-
A) expresses the full-length NIK with a mutation in the kinase domain that abrogates its 
kinase activity.  Transfection of NIK (K-A), but not DNNIK or DNNIKaly, reduced CTAR1-
induced EGFR expression significantly by 35%.  Similarly, NIK (K-A) decreased CTAR1-
induced serine phosphorylation of STAT3 by 34%, while DNNIK and DNNIKaly did not 
have significant effects.  These findings indicate that NIK contributes to the EGFR 
upregulation by LMP1 through mediating induction of STAT3 serine phosphorylation.    
To determine whether NIK itself is sufficient to induce ser-pSTAT3 and EGFR 
upregulation, wild-type NIK was transiently transfected into both C33A and 293T cells and 
EGFR expression and ser-pSTAT3 were assessed by western blot analysis (Figure 3B).  NIK 
expression was clearly detected in 293T cells, however, overexpression of NIK did not 
induce ser-pSTAT3 or EGFR expression.  In C33A cells, transfection of 4μg of NIK very 
slightly increased ser-pSTAT3, however failed to induce expression of EGFR.  To determine 
whether NIK perhaps requires activation of additional pathways affected by CTAR1 to 
induce STAT3 activation and EGFR expression, CTAR1-expressing NIK-defective MEF 
cells were also transfected with increasing amounts of the WT NIK construct.  Expression of 
CTAR1 was confirmed by western blot analysis using antibody to the HA tag and the effects 
on EGFR and ser-pSTAT3 were determined (Figure 3C).  Similarly to the results observed in  
128 
 
NIK-/-MEF
WTNIK(ug) 0 0 0.5 1 2 4
CTAR1
NIK
Ser-P-STAT3
HA(CTAR1)
GAPDH
EGFR
0 0.5 2 4
C33A
WTNIK(ug)
NIK
Ser-P-STAT3
GAPDH
293T
0 0.5 2 4
EGFR
B)
C)
A)
EGFR
GAPDH
 - + + +  +CTAR1
C33A
NIK
Relative level 1 4.45 5.64 2.93 4.84
Ser-P-STAT3
0
0.2
0.4
0.6
0.8
1
1.2
CTAR1 DMSO CTAR1 DNNIK CTAR1 NIK(K-A) CTAR1 NIKaly
*
EGFR level
Fo
ld
(n
or
m
al
iz
ed
to
G
A
PD
H
)
 
 
 
 
 
 
 
 
 
 
 
Fig 3.  Blocking NIK reduces LMP1-induced EGFR expression, but overexpression of NIK 
is not sufficient to mimic LMP1-mediated EGFR upregulation.  A) C33A cells stably 
expressing CTAR1 was transfected with pCDNA3 control vector or dominant-negative NIK 
construct (DNNIK), DNNIK construct with aly-mutation (G860R; DNNIKaly), or kinase-
dead NIK (NIK (K-A)).  Expression level of serine-phosphorylated STAT3 and EGFR were 
analyzed by immunoblotting.  Expressions of NIK mutants were detected by 
immunoblotting using antibody against C-terminus of NIK.  Expression of GAPDH was 
measured by immunoblotting as loading control.  Intensity of ser-P-STAT3 and EGFR 
bands were quantitated by Image J software and normalized to the expression level of 
GAPDH from three independent experiments.  *P<0.05.  B) C33A and 293T cells were 
transfected with increasing amount of wild-type NIK expression construct.  C) NIK-
defective MEF cells stably expressing CTAR1 were transfected with increasing amount of 
wild-type NIK expression construct.  CTAR1 expression was confirmed by immunoblotting 
with antibody against HA-tag.  Expression of NIK, EGFR, and serine-phosphorylated 
STAT3 were analyzed with immunoblotting.  Expression of GAPDH was measured by 
immunoblotting as loading control. 
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293T and C33A cells, overexpression of NIK in NIK-defective MEF cells was not sufficient 
to induce either ser-pSTAT3 or EGFR induction, even in the presence of CTAR1.  These 
results suggest that although NIK is required for CTAR1-mediated EGFR upregulation, NIK 
overexpression alone is not sufficient to induce these pathways and additional factors or 
processes are required for ser-pSTAT3 or EGFR expression.   
CTAR1-mediated p50 activation is not dependent on the canonical or 
noncanonical NF-κB pathways.  LMP1 induction of EGFR transcription is mediated 
through effects on Bcl-3 and induction of p50-homodimers (25, 52, 53).  To determine the 
requirement for specific IKK complexes on CTAR1-mediated p50 activation, CTAR1-
expressing wild-type, IKKβ-, IKKγ-, and NIK-defective MEF cells were fractionated and the 
nuclear lysates analyzed to detect nuclear expression of p65, p50, and RelB (Figure 4).  The 
expression of PARP was analyzed as a loading control for the nuclear lysates.  Nuclear 
translocation of p65 is characteristic of the canonical pathway and p65 was detected in the 
nuclear lysates from WT, IKKγ-, and NIK-defective MEFs but not in IKKβ-defective cells.  
Nuclear RelB is the major form of NF-κB that represents the noncanonical pathway and 
CTAR1 induced nuclear translocation of RelB in wild-type and IKKβ-defective MEF cells, 
but not in NIK-defective cells.  These findings confirm that CTAR1-mediated translocation 
of p65 reflects activation of the canonical pathway and that the effects of LMP1 on RelB 
require the noncanonical pathway.  In contrast, the nuclear expression of p50 was 
significantly induced by CTAR1 in IKKβ-, IKKγ- and NIK-defective MEF cells.  This 
indicates that CTAR1-mediated p50 activation and nuclear translocation are distinct from 
both the canonical and noncanonical NF-κB pathways.  A high basal level of nuclear p50 was 
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detected in wild-type MEF cells and may be linked to the higher level of EGFR in wt-MEFs 
and the slight effects of LMP1 on EGFR expression compared to that in C33A cells. 
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LMP1-mediated p50 activation is proteasome-dependent.  The mechanisms 
responsible for p50 activation have not been clearly defined.  Several studies have indicated 
that p50 can be activated by a proteasome-dependent mechanism that either modulates p105 
processing or impairs ribosomal progression (23).   To determine whether p50 is activated by 
CTAR1 through proteasome-mediated mechanisms, C33A cells stably transduced with 
vector or CTAR1 were treated with DMSO or proteasome inhibitors, MG132 (26S inhibitor) 
or clasto-Lactacystin β-Lactone (20S inhibitor) (Figure 5).  The effects of these inhibitors on 
p105/50 were assessed by immunoblotting anti-p105/50 antibodies.  β-catenin is a known 
Fig 4.  CTAR1-mediated p50 activation is not dependent on canonical or noncanonical 
pathway.  Wild-type, IKKβ-/-, IKKγ-/-, and NIKaly/aly MEF cells stably transduced with 
vector or CTAR1 were fractionated and nuclei lysates were subjected to immunoblot 
analysis with antibodies specifically against p65 (RelA), p50, and RelB.  PARP expression 
was analyzed by immunoblotting as loading control. 
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target of proteasomal degradation and was analyzed as a positive control for inhibition of 
proteasome activity.  GAPDH and Emerin were analyzed as loading control for whole cell 
lysates and nuclear lysates, respectively.  In CTAR1-expressing C33A cells where nuclear 
expression of p50 is significantly induced, treatment with 1μM or 10μM of MG132 reduced 
p50 translocation level by 72% and 64%, respectively (Figure 5A).  Similarly, treatment with 
1μM or 10μM of clasto-Lactacystin β-Lactone reduced CTAR1-induced p50 nuclear 
translocation by 35% and 69%, respectively.  Nuclear p50 was not detected in the C33A cells 
transduced with the pBabe control plasmid, and treatment with proteasome inhibitors did not 
have a significant effect (data not shown).  This result indicates that LMP1-CTAR1 induces 
p50 activation and nuclear translocation are mediated through effects on proteasome activity. 
CTAR1 did induced the expression of β-catenin in C33A cells which is consistent 
with findings that LMP1 affects the expression of junctional proteins (49).  In cells treated 
with proteasome inhibitors, β-catenin levels were increased and a higher molecular weight 
forms of β-catenin was detected, reflecting its ubiquitination and the successful inhibition of 
proteasomal activity.  The level of p105-to-p50 processing was determined by calculating the 
ratio of p50 to the total p105/50 complex in whole cell lysates of C33A cells transduced with 
pBabe control or CTAR1 (Figure 5B).  The processing of p105 to p50 was enhanced by 
approximately 15% in CTAR1-expressing C33A cells compared to pBabe control cells.  
After MG132 treatment, the percentage of processed p50 was not significantly affected in 
either vector control or CTAR1-expressing cells.  Treatment with 20S proteasomal inhibitor 
clasto-Lactacystin β-Lactone did not affect p50 processing in pBabe control cells.  However, 
treatment of 10μM clasto-Lactacystin β-Lactone reduced p50 processing in CTAR1-
expressing cells to approximately 40%, which is similar to the level observed in pBabe    
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Fig 5.  CTAR1 mediates p50 activation through proteasome-dependent pathways.  C33A 
cells stably transduced with vector control or CTAR1 were treated with DMSO or 
proteasome inhibitor MG132 or β-lactone (1 or 10μM) for 5 hours and subjected to 
fractionation.  A) Nuclear lysates and B) Whole cell lysates of these cells were analyzed by 
immunoblotting.  Antibody against p105/50 was used to detect the processing and 
activation of p50.  Expression of GAPDH and Emerin were detected as loading controls for 
whole cell lysates and nuclear lysates, respectively.   Intensity of p105/50 bands were 
quantitated by Image J software and percentage of processed p50 in whole cell lysates was 
calculated by [p50 / (p50+p105)] × 100%.  The level of p50 nuclear expression was 
quantitated by normalizing p50 to the expression level of Emerin. 
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control cells.  These findings indicate that LMP1-CTAR1 mediates proteasome-dependent 
mechanisms to induce p50 activation.  
LMP1-mediated EGFR induction requires TRAF2 and TRAF3, but not TRAF6.   
Initial studies showed that the TRAF-binding motif of LMP1 was required for CTAR1-
induced EGFR expression and NF-κB activation and these effects were decreased by 
dominant negative TRAF2 and TRAF3 (36, 38).  To further evaluate this requirement, LMP1 
and LMP1-CTAR1 were expressed in MEF cells deficient for TRAF2, TRAF3, or TRAF6 
(Figure 6).  The expression levels of EGFR, and LMP1 and deletion mutants were 
determined using immunoblotting of whole cell lysates (Figure 6A).  LMP1 and CTAR1 
were detected using antibodies against the HA- or myc-epitope tags.  EGFR was expressed at 
high levels in TRAF2-/- MEFs, intermediate levels in TRAF3-/- MEFs, and was barely 
detected in TRAF6-/- MEFs.  This confirmed that the presence and absence of TRAFs 
modulate expression of the EGFR.  Expression of LMP1 or CTAR1 changed these patterns 
of expression.  In the TRAF2-null and TRAF3-null MEFs, LMP1 or CTAR1 expression did 
not increase EGFR expression.  In contrast, in the TRAF6-null MEFs, LMP1 and CTAR1 
clearly induced EGFR expression.  The ability of LMP1-CTAR1 to induce EGFR in TRAF6-
null MEFs but not in TRAF2- or TRAF3-null MEFS is consistent with previously identified 
interactions between CTAR1 with TRAF2 and TRAF3 but not with TRAF6.   
The nuclear level of p50 was also analyzed in TRAF2-/-, TRAF3-/-, and TRAF6-/- 
MEFs by immunoblotting (Figure 6B).  Compared to the vector control cells, CTAR1 
induced nuclear expression of p50 in TRAF3-/- and TRAF6-/- cells but did not affect nuclear 
p50 levels in TRAF2-/- MEF cells that had elevated basal nuclear p50.  These results indicate 
that TRAF3 and TRAF6 are not required for LMP1-CTAR1 effects on p50 activation and  
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that in the absence of TRAF2, nuclear levels of p50 are elevated and LMP1-CTAR1 did not 
further increase nuclear p50.  TRAF6 was not required for CTAR1-mediated effects on p50 
translocation and EGFR upregulation.   
 
Fig 6.  LMP1-mediated EGFR upregulation is TRAF2- and TRAF3-, but not TRAF6-
dependent.  A) TRAF2-/-, TRAF3-/-, and TRAF6-/- MEF cells were transfected or 
transduced with vector control, full-length LMP1, CTAR1 or CTAR2, and whole cell 
lysates of these cells were subject to immunoblotting with EGFR-specific antibodies.  
Expressions of LMP1 or CTAR1 were confirmed by immunoblotting with specific 
antibody against full-length LMP1 (S12), HA-tag or Myc-tag.  Expression of GRP78 was 
detected as loading control.  B) TRAF2-/-, TRAF3-/-, and TRAF6-/- MEF cells expressing 
CTAR1 were fractionated and nuclear lysates were analyzed by immunoblotting with p50 
antibody.  Expression of PARP was detected as loading control.   
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DISCUSSION 
LMP1 is a member of the TNFR family and potently activates NF-κB transcriptional 
activity.  Early studies identified that two distinct NF-κB activating domains in the carboxy 
terminus, CTAR1 and CTAR2 and determined that CTAR2 had greater activity in NF-κB 
reporter assays (19, 43).  However, identification of the specific complexes using 
electrophoretic mobility shifts assay (EMSA) revealed that CTAR1 activated multiple forms 
of NF-κB while CTAR2 primarily activated a complex containing p65.  In addition, it was 
shown that CTAR1 significantly enhanced processing of p100 to p52.    Subsequent studies 
have further characterized activation of NF-κB and defined the canonical pathway that 
involves the IKK complex containing IKKα, IKKβ, and IKKγ  to phosphorylate and 
negatively regulate the inhibitor of NFkB, IκBα.  It is now known that CTAR2 activates 
IKKγ (NEMO) / IKKβ-dependent canonical NF-κB pathway through TRAF6 / IRAK1 / 
TAK1 (30, 47, 57).  CTAR1, on the other hand, activates IKKγ (NEMO)-independent but 
NIK / IKKα-dependent noncanonical NF-κB pathway, in addition to some activation of the 
canonical pathway (1, 9, 31).  An atypical IKKβ-dependent / IKKγ-independent NF-κB 
activation has also been previously described in LMP1-expressing cell culture models (31).  
Our previous studies have identified an additional LMP1-mediated activation of NF-κB, in 
which CTAR1 of LMP1 activates two NF-κB members, p50 and Bcl-3, that are induced to 
bind to the EGFR promoter by LMP1 and increase EGFR transcription (25, 52, 53).  The 
data in this study indicate that this novel pathway is independent of factors required for 
activation of the canonical or noncanonical NF-κB pathways.  IKKα, IKKβ, and IKKγ, all 
important components in canonical NF-κB pathway, were not required for CTAR1-induced 
EGFR expression (Figure 2).  This result is consistent with previous data indicating that 
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CTAR2 alone was not able to induce EGFR expression despite its ability to activate strong 
canonical NF-κB signaling (Figure 1) (25, 36).  Although the CTAR1-mediated EGFR 
induction was inhibited in NIKaly/aly cells, perhaps suggesting a requirement for the 
noncanonical NF-κB pathway, CTAR1-mediated induction of EGFR did not require IKKα, 
the functional kinase in the noncanonical NF-κB pathway.  The decreased EGFR induction 
by the dominant-negative NIK constructs, kinase-dead NIK (K-A), in CTAR1-expressing 
C33A cells suggests that NIK does contribute to CTAR1-mediated EGFR induction (Figure 
3A).  The lack of effect by DNNIKaly on CTAR1-induced EGFR expression suggests that 
specific protein interactions and functions mediated through the aly residue (G860R) is 
important for EGFR upregulation.  This result is consistent with the observation that CTAR1 
could not induce EGFR expression in NIKaly/aly MEF cells.  In contrast to NIK (K-A), 
DNNIK did not significantly reduce CTAR1-induce STAT3 serine phosphorylation and 
EGFR expression, despite both constructs contain the TRAF/IKK binding domain.  This 
result indicates that N-terminus of NIK also contributes to EGFR upregulation.  NIK 
expression was not sufficient for CTAR1-mediated STAT3 activation and EGFR 
upregulation in epithelial cells, and overexpression of wild-type NIK in the presence of 
CTAR1 did not induce ser-pSTAT3 or EGFR induction in NIK deficient cells (Figure 3B and 
3C).  These findings suggest that additional potentially NIK-associated factors or NIK-
mediated effects on other kinases contribute to this pathway and that a balance of expression 
level between NIK and NIK-associated factors may be required.  These findings are similar 
to the requirement for TRAF3 for LMP1 signaling.  Although TRAF3 is required for LMP1-
mediated signaling pathways and transformation, overexpression of TRAF3 in LMP1-
expression cells impairs CTAR1-mediated NF-κB activation (2, 34, 36, 38).  TRAF3 binds 
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strongly to CTAR1 and its overexpression likely alters the components in the LMP1/TRAF 
complexes that activate NF-κB. 
It is known that both TRAF3 and TRAF2 regulate NIK and it is thought that TRAF3 
is required to form a complex containing TRAF2 and cIAP that induces NIK turnover (54).  
This suggests a negative regulatory mechanism between TRAF2/TRAF3 and NIK.  
However, CTAR1 failed to induce EGFR expression in MEF cells defective for TRAF2, 
TRAF3, or NIK.  It is  possible that LMP1-CTAR1 may mediate EGFR upregulation through 
NIK by sequestering NIK regulators TRAF2 and TRAF3.  This hypothesis would be 
consistent with the ability of LMP1 to modulate formation of TRAF-containing complexes 
and their effects on various targets. 
The other important member of EGFR-inducing complex, p50 is activated and 
translocated into the nucleus in LMP1/CTAR1-expressing C33A cells (25, 43, 53).  Several 
mechanisms have been suggested to mediate p50 activation.  This study reveals that CTAR1-
induced p50 activation is not dependent on either canonical or noncanonical NF-κB pathway 
since this  occurred in IKKβ-, IKKγ- and NIK-defective MEF cells (Figure 4).  Interestingly, 
CTAR1 did not induce significant p50 activation in wt-MEF cells.  This may be due to the 
relatively high level of nuclear p50 in wt-MEF cells, and may partially explain why LMP1 
only slightly induced EGFR expression in wt-MEF cells compared to C33A or other mutant 
MEF cells.   
Multiple studies have suggested that p50 can be activated through processing of its 
precursor, p105.  This processing could occur in ubiquitination-dependent or ubiquitination-
independent fashions (3, 5, 23, 39).  It was also suggested that p50 could be generated 
through a mechanism involved cotranslational ribosome halting (28, 29).  One consensus 
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among these suggested mechanism is that they are all proteasome-dependent.  The data 
presented here indicate that CTAR1 indeed induces processing of p50, which is consistent 
with previous studies (43).  Proteasome inhibition with both 26S and 20S inhibitors reduced 
p50 activation in CTAR1 expressing cells (Figure 5).  These results indicate that CTAR1 
activates p50 in part through proteasome-dependent processing of p105 to p50.  Interestingly, 
both 26S inhibitor MG132 and 20S inhibitor clasto-Lactacystin β-Lactone inhibit CTAR1-
induced nuclear translocation of p50, but only clasto-Lactacystin β-Lactone reduced 
processing of p105 to p50 in CTAR1 cells to a  level similar to that in pBabe control cells.  
This suggests that while 20S proteasome is responsible for CTAR1-mediated processing of 
p50,  MG132 blocks separate pathways that contribute to CTAR1-induced p50 activation 
(39).  It is possible that both MG132 and clasto-Lactacystin β-Lactone block CTAR1-
mediated nuclear translocation of p50, which only accounts for a small subset of CTAR1-
induced p50 processing and the differences may not be detectable in the total cell lysates.  It 
is likely that LMP1 regulates multiple pathways to mediate p50 activation.  This is supported 
by the observation that CTAR1 induced p50 activation in MEF cells defective for IKKβ, 
which has been suggested as the kinase responsible for p105 processing (5).  Moreover, 
LMP1-CTAR1 could also affect regulatory pathways to induce p50 translocation.  Several 
proteins have been suggested previously to regulate p50 translocation, including Bcl-3 and 
Importin-3α (12, 59).  The fact that LMP1-CTAR1 induces Bcl-3 expression and nuclear 
localization makes it an attractive candidate (25, 41).  It will be of interest to determine if 
Bcl-3 and Importins contribute to CTAR1-mediated p50 activation and induction of EGFR. 
LMP1-associated TRAFs are important for LMP1-mediated signaling pathways, 
including JNK, p38, and NF-κB activation (51).  Our initial studies indicated that the TRAF-
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binding motif of CTAR1 was required for LMP1 induction of EGFR expression (36).  
Expression of CTAR1 in MEF cells defective for different TRAFs revealed that TRAF2 and 
TRAF3, but not TRAF6, are required for CTAR1-mediated EGFR induction (Figure 6).  This 
result is consistent with the findings that TRAF2 and TRAF3, but not TRAF6, interact with 
CTAR1 TRAF-binding motif.  TRAF2 may contribute to EGFR induction by regulating p50 
activation, while TRAF3 may contribute to EGFR induction through independent pathways.  
It has been suggested that kinase Tpl-2/Cot functions downstream of TRAF2 to modulate 
p105 degradation (10).  It will be interesting to see if Tpl-2/Cot plays a role in LMP1-
induced EGFR expression.  Although TRAF6 does not interact with CTAR1, it has been 
shown that TRAF6 can interact with NIK (6).  It is possible that the interaction of CTAR2 
with TRAF6 modulates the TRAF6 interaction with NIK and NIK-regulated activation of 
ser-pSTAT3 or downstream kinases.  LMP1 containing CTAR1 but deleted for CTAR2 
usually has elevated effects in comparison to full-length LMP1 in C33A cells (25).  The 
effects of the two domains on various TRAF containing complexes are likely the basis for the 
enhanced activity of CTAR1 in the absence of CTAR2.  It is also interesting to note that 
another potential STAT3 kinase, ERK, has been shown to be regulated by NIK and CTAR1-
mediated ERK activation and transformation was also inhibited by dominant-negative 
TRAF2 or TRAF3, but not TRAF6 (13, 34).  The interaction of LMP1 with TRAF2 and 
TRAF3 likely activates multiple potentially redundant kinases that affect transcription factors 
that regulate EGFR expression.   
In conclusion, this study reveals that LMP1-CTAR1 induces EGFR expression 
through NIK, TRAF2, and TRAF3 independently of traditionally-defined canonical and 
noncanonical NF-κB pathways.  Two important EGFR-inducing factors, STAT3 and p50, are 
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regulated distinctively in the presence or absence of various IKK and TRAF molecules.  The 
effects of LMP1 on the ser-pSTAT3 potentially require NIK, whereas the effects on p50 
require TRAF2 but are independent of NIK, TRAF3, and TRAF6.  Additionally, LMP1-
CTAR1 activates p50 through proteasome-dependent processing of p105 to p50.  The data 
suggest that distinct combinations of LMP1-activated effectors regulate the effects of LMP1 
expression and its ability to induce transformation.  The further study of LMP1 and its 
activation of NF-κB and additional pathways will likely clarify the link between specific 
signal transducing complexes and the downstream effectors, as well as its contribution to 
EBV-associated cancer development.  
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ABSTRACT 
Epstein-Barr virus is a ubiquitous herpesvirus that infects more than 90% of the 
world’s adult population and is linked to multiple malignancies, including Burkitt lymphoma, 
Hodgkin disease, and nasopharyngeal carcinoma (NPC).  The EBV oncoprotein LMP1 
induces transcription of the epidermal growth factor receptor (EGFR), which is expressed at 
high levels in NPC.  EGFR transcription is induced by LMP1 through a p50 homodimer-Bcl3 
complex, and Bcl3 is induced by LMP1 activation of STAT3.   This study reveals that 
LMP1, through its carboxy terminal activation domain 1 (CTAR1), activated both STAT3 
and EGFR in a serum-independent manner.  LMP1-CTAR1 increased transcription of the 
EGFR ligand, epiregulin, which could potentially activate the EGFR through an autocrine 
mechanism.   Upon treatment with EGF in serum-free medium, the CTAR1-induced EGFR 
was additionally phosphorylated and STAT3 became phosphorylated on tyrosine, 
concomitant with upregulation of selected STAT3 target genes, such as Fos and cyclin D1.  
The kinase responsible for CTAR1-mediated serine phosphorylation of STAT3 was 
identified to be PKCδ using the PKCδ specific inhibitor, Rottlerin.  Interestingly, Rottlerin 
also inhibited CTAR1-induced ERK activation while the ERK inhibitor, U0126, inhibited 
activation of ERK but not STAT3.  Inhibition of PKCδ blocked CTAR1-mediated 
transformation of Rat-1 cells, likely through the inhibition of ERK activation.  These data 
suggest that PKCδ functions as a master regulator of STAT3 and ERK activation by LMP1-
CTAR1.  These data also reveal that LMP1 can modulate the STAT3 pathway through EGFR 
activation and PKCδ-mediated signaling to alter cellular gene expression.   
 
INTRODUCTION 
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Infecting more than 90% of the world’s population, the Epstein-Barr virus (EBV) is a 
ubiquitous human gammaherpesvirus.  EBV is transmitted through saliva to infect oral 
epithelium and B-lymphocytes resulting in a life-long infection (21).  Persistent, latent EBV 
infection is present in several lymphoid and epithelial malignancies, including Burkitt 
lymphoma, Hodgkin disease, and nasopharyngeal carcinoma (NPC).  Viral genes of latent 
infection are expressed in the malignant cells, which contain a homogeneous clonal form of 
the EBV episome (41). 
EBV latent membrane protein 1 (LMP1) is considered the major oncogene as it is 
essential for B-lymphocyte transformation and can also transform rodent fibroblast cells (20, 
56).  LMP1 functions as a constitutively active tumor necrosis factor receptor (TNFR) due to 
aggregation through its six transmembrane domains and interactions with tumor necrosis 
factor-associated factors (TRAFs) (33, 37).  Multiple signaling pathways are activated by 
LMP1, including mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK), 
phosphatidylinositol 3-kinase (PI3K)/Akt, and NF-κB  (8, 31, 38, 42).  LMP1 induces 
transcription of multiple genes to affect apoptosis, cell cycle progression, cell proliferation, 
and migration (10, 11, 46).  Two major signaling domains in the C-terminal tail of LMP1, 
carboxyl-terminal activating regions 1 and 2 (CTAR1 and CTAR2), mediate LMP1-
associated signaling pathways by recruiting different TRAFs.  CTAR1 recruits TRAF1/2/3/5 
through a TRAF-binding motif residing from amino acid (aa) 204-208 (PQQAT), whereas 
CTAR2 recruits TRAF2 and TRAF6 through adaptors TRADD and BS69 (50). 
In addition to distinctive TRAF binding, CTAR1 and CTAR2 also have different 
effects on signaling activation and cellular transformation.  CTAR1 specifically induces 
MAPK, PI3K/Akt/GSK3β signaling, while CTAR2 activates the JNK pathway (7, 31, 32).  
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CTAR2 activates strong canonical NF-κB signaling, whereas CTAR1 induces  more complex 
NF-κB signaling including canonical, noncanonical, and atypical pathways (29, 33).  
Moreover, CTAR1 has been shown to be required for LMP1-mediated transformation of B-
lymphocyte and rodent fibroblast, while CTAR2 is dispensable (17, 31).  This information 
suggests that CTAR1 may have more significant effects in the development of malignancy.  
The unique properties of CTAR1 were first identified in its ability to induce transcription of 
the EGFR and subsequently TRAF1, EBI3, Id1, and Id3, repression of p27, and activation of 
Bcl-3 have been identified (6, 10, 25, 33). 
EGFR is a member of the ErbB receptor tyrosine kinase family, including EGFR 
(ErbB-1), HER2/c-neu (ErbB-2), HER3 (ErbB-3), and HER4 (ErbB-4).  In the absence of 
ligand, these receptors are in an inactive tethered conformation (57).  Upon ligand binding, 
the receptors undergo dimerization, autophosphorylation, activation, and subsequently 
degradation/turnover.  Multiple signaling pathways are activated by the EGFR, including 
Ras/MAPK, Src kinases, JAKs/STATs, and PI3K-AKT (19).  EGFR signaling is targeted by 
proteins of several oncogenic viruses to mediate transformation, including v-ErbB, E5, 
HBVx, and LMP1 (35).  NPC has elevated EGFR expression which correlated with the levels 
of LMP1 and treatment with EGFR tyrosine kinase inhibitors induces cell cycle arrest and 
inhibits cell proliferation of NPC cell lines (58, 59).  These findings suggest that the effect of 
LMP1 on EGFR is an important factor in EBV carcinogenesis and is a prime target for 
development of therapeutic strategies. 
Signal transducers and activators of transcription (STATs) consist of a family of 
cytoplasmic proteins that, upon stimulation of cytokines or growth factors, translocate into 
the nucleus and transactivate cellular target genes that are involved with cell proliferation, 
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cell cycle regulation, apoptosis, angiogenesis, and differentiation (22).  The transcriptional 
activity of STAT3 is regulated by phosphorylation.  Phosphorylation of tyrosine 705 and 
serine 727 affect dimerization/translocation and the DNA-bindng/transcriptional activity of 
STAT3, respectively (1) .  In NPC and B-cell lymphomas that develop in LMP1-transgenic 
mice, STAT3 is activated (2, 45).  A positive autoregulatory loop, in which LMP1-activated 
STAT3 regulates LMP1 expression through effects on the novel LMP1 promoter residing in 
the terminal repeats has been described (4).  LMP1-mediated STAT3 activation is also 
responsible for several LMP1-induced cellular genes, including MUC1 and Bcl-3 (23, 25).  
LMP1-mediated tyrosine phosphorylation of STAT3 has been linked to JAK1 or JAK3, 
although whether LMP1 interacts directly with JAKs is controversial (13, 15).  The 
mechanism through which LMP1 induces serine phosphorylation of STAT3 is unknown. 
This study clarifies the mechanisms through which EGFR and STAT3 are activated 
by EBV LMP1-CTAR1.  CTAR1 was found to induce activation of EGFR, STAT3, and Bcl-
3 expression in a serum-independent manner.  EGF treatment increased phosphorylation of 
EGFR, tyrosine phosphorylation of STAT3, and upregulation of STAT3 targets.  
Transcription of the EGFR ligand, epiregulin, was induced in CTAR1-expressing cells, 
suggesting that this may promote the continuous activation of the EGFR by LMP1.  The data 
also indicate that the CTAR1-induced serine phosphorylation of STAT3 is dependent on 
PKCδ, whose inhibition also impaired LMP1-induced ERK activation and CTAR1-mediated 
transformation of Rat-1 cells.  These data reveal that multiple LMP1-mediated signaling 
pathways, including effects on EGFR, STAT3, and PKCδ contribute to the transforming 
properties of LMP1. 
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MATERIALS AND METHODS 
Cell Culture, plasmids, and reagents 
Cervical carcinoma cell line C33A and 293T cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM; Gibco) supplemented with 10% fetal bovine serum 
(Sigma) and antibiotic/antimycotic (Gibco) at 37°C with 5% CO2.  Constructs expressing 
HA-tagged (pBabe) LMP1-CTAR1 (which contains aa 1-231 of LMP1) and LMP1(1-220) 
were generated as described previously (10, 32).  Small chemical inhibitors, including 
Rottlerin, Gö6976, U0126, LY294002, and AG1478 were purchased from Calbiochem.  To 
test the effects of inhibitors on CTAR1-mediated pathways, growth medium was replaced 
with serum-free DMEM supplemented with antibiotic/antimycotic for 24 hours.  Inhibitors 
were added for 5 hr before preparing lysates.  Dimethyl sulfoxide (DMSO; Sigma) was 
added at 1:1000 as the vehicle control.  To test the activity of EGFR, serum-starved cells 
were added with 500ng/ml EGF (Austral Biologicals) and 100μM AG1478 for 10 or 30 min 
before harvesting cell lysates. 
Retrovirus production and transduction 
Recombinant retrovirus production and retroviral transduction were performed as 
previously described (32).  Subconfluent 293T cells in 100mm plates were transfected by 
FuGENE 6 transfection reagent (Roche) with 5µg pBabe (vector), pBabe-HA-1-231, or 
pBabe-HA-1-220, and 5µg pVSV-G and 5µg pGag/Pol expressing plasmids.  After 
incubating at 37°C for 24 hr, the medium was replaced with fresh medium (DMEM 
supplemented with 10% FBS and antibiotic/antimycotic) and cells were incubated at 33°C 
for 24 hr.  The cell supernatant was clarified and the virus-containing supernatant was 
collected.  Stable cell lines were produced by transduction with clarified virus supernatant 
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with 4µg/ml polybrene for 24 hr at 37°C, followed by selection with 1μg/ml of puromycin 
(Sigma).  
Cell lysates harvesting and western blot analysis 
Cells were harvested at 90% confluence, washed with cold phosphate-buffered saline 
(PBS, Gibco), scrape harvested in cold PBS, centrifuged at 1000 × g for 5 min, and lysed 
with radioimmunoprecipitation assay (RIPA) buffer (20mM Tris-HCl [pH 7.5], 150mM 
NaCl, 1mM EDTA, 1% NP-40, 0.1% sodium dodecyl sulfate [SDS], 0.1% deoxycholic acid) 
supplemented with 0.5mM phenylmethylsulfonyl fluoride (PMSF), 1mM sodium 
orthovanadate (Na3VO4), protease and phosphatase inhibitor cocktail (Sigma).  Cell lysates 
were clarified and the protein concentration was determined using Bio-Rad DC protein assay 
system.  Equal amounts of protein were used for SDS-polyacrylamide gel electrophoresis 
(PAGE) and transferred to Optitran (Schleicher and Schuell) for Western blot analysis.  
Membranes were blocked for 1 hr in room temperature in Tris-buffered saline containing 
0.1% Tween-20 and 5% nonfat dried milk.  Primary antibodies include anti-GAPDH, anti-
ERK, anti-phospho-ERK (Tyr 473) (Santa Cruz), anti-phospho-Akt (Ser 473), anti-phospho-
STAT3 (Ser 727 and Tyr 705), anti-PKCδ (Cell Signaling), anti-phospho-EGFR (Tyr 1068) 
(BD Biosciences), anti-Bcl3 (Millipore), and anti-HA tag (Covance).  A rabbit antiserum 
generated against the carboxyl-terminal 100 amino acids of the EGFR fused to glutathione S-
transferase was kindly provided by H. Shelton Earp (University of North Carolina at Chapel 
Hill) and used to detect expression of total EGFR.  Secondary antibodies used to detect Abs-
bound proteins include HRP (horseradish peroxidase)-conjugated anti-mouse, anti-rabbit 
(Amersham Pharmacia), and anti-goat (DAKO).  After incubation with secondary antibodies, 
154 
 
blots were developed using Pierce Supersignal West Pico chemiluminescence system 
according to the manufacturer’s instructions, followed by exposure to films (ISCBioexpress). 
Quantitative Real Time Polymerase Chain Reaction (QRT-PCR) 
Total RNA of cells was isolated using RNAeasy kit (Qiagen).  Quantitative real time-
PCR (QRT-PCR) was performed using Quantifast SYBR Green RT-PCR kit (Qiagen).  PCR 
products were detected using ABI 7900HT sequence detection system (Applied Biosystems) 
and analyzed using SDS 2.0 software (Applied Biosystems).  The cycle threshold (CT) was 
determined as the number of PCR cycles required for reactions to reach an arbitrary 
fluorescence value within the linear amplification range.  The change in CT (∆CT) was 
determined between the same target gene primer sets and different samples, and the change 
in ∆CT (∆∆CT) was determined by adjusting for the difference in the number of cycles 
required for GAPDH to reach the CT.  The fold change was determined as 2∆∆CT since each 
PCR cycle results in a two-fold amplification of PCR products.  Primers used in this study 
are listed in Table S1. 
 Focus formation assay 
Focus formation assays were performed as described previously (31).  Subconfluent 
Rat-1 fibroblast cells plated in 6-well plates were transduced with recombinant retrovirus for 
24 hr.  Fresh medium (DMEM supplemented with 10% fetal bovine serum and 
antibiotic/antimycotic) were then changed every other day for 10 days.  The effect on focus 
formation by inhibition of PKCδ using Rottlerin was determined using 1μM Rottlerin or 
vehicle control DMSO added daily with freshly-changed medium.  After foci can be clearly 
identified, cells were stained with 1% crystal violet (dissolved in 50% methanol) and images 
were taken under a stereomicroscope. 
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Data Analysis 
The quantitative data were presented as the average value of at least triplicate of each 
experiment ± SE.  Statistical significance was evaluated using a computerized, paired 2-tailed 
Student t test.  Differences were considered significant at P < 0.05. 
 
 
 
 
Target 
genes 
Primer sequence (from 5’ to 3’) 
Forward Reverse 
GAPDH TGCACCACCAACTGCTTAGC GAGGGGCCATCCACAGTCTT 
EGFR CTGCGTCTCTTGCCGGAATG  TTGGCTCACCCTCCAGAAGG 
TGFα GCCAGCATGTGTCTGCCATT CACCACCAAGGCGGTGA 
HB-EGF TGGAGAATGCAAATATGTGAAGGA AGGATGGTTGTGTGGTCATAGGTAT 
Epiregulin TTCCATCATGTATCCCAGGAG ATTGACACTTGAGCCACACG 
SOCS3 CCTCAAGACCTTCAGCTCCA  TCACTGCGCTCCAGTAGAAG 
Bcl-xL CTTGGATGGCCACTTACCTG TGCTGCATTGTTCCCATAGA 
Fos AAGGAGAATCCGAAGGGAAA  AGTTGGTCTGTCTCCGCTTG 
CEBPD ATCGACTTCAGCGCCTACAT  GCCTTGTGATTGCTGTTGAA 
Cyclin D1 GATCAAGTGTGACCCGGACT  TCCTCCTCTTCCTCCTCCTC 
Table 1.  Quantitative RT-PCR primers 
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RESULTS 
LMP1 induces intrinsic activation of STAT3 and EGFR, as well as EGFR-
dependent STAT3 phosphorylation.  We have shown previously that LMP1, through 
CTAR1, induces EGFR expression through activation of NF-kB p50 and transcriptional 
upregulation of Bcl-3 by activated STAT3 (25, 34, 53).  To investigate the effects of LMP1 
on activation of EGFR and STAT3, C33A cells stably transduced with CTAR1 were cultured 
in 10% serum or serum-starved for 24 hr and whole cell lysates were analyzed by 
immunoblotting (Figure 1).  In serum-supplemented medium CTAR1 induced expression and 
activation of EGFR as assessed by EGFR phosphorylation at Tyr1068 (lane 2).  CTAR1 also 
induced expression of Bcl-3 and both tyrosine and serine phosphorylation of the 
transcriptional activator STAT3 but did not affect the total level of STAT3.  Interestingly, 
EGFR and STAT3 were still phosphorylated and activated in the absence of serum, and 
expression of Bcl-3 was induced to similar levels as cells grown in 10% FBS (lane 3).  These 
data indicate that CTAR1-mediated EGFR and STAT3 activations are independent of the 
presence of growth factors in the medium.   
It has been suggested that EGFR interacts with STAT3 and can function as tyrosine 
kinase to activate STAT3 (40).  To determine whether CTAR1-induced EGFR can be further 
stimulated to activate STAT3, serum-starved CTAR1-expressing C33A cells were treated 
with 500ng/ml of EGF with or without EGFR kinase inhibitor, AG1478, and analyzed by 
Western blotting.  Treatment with EGF for 10 minutes greatly increased the tyrosine 
phosphorylation of STAT3 (lane 4) but did not affect the serine phosphorylation of STAT3 
or expression of Bcl-3.  The EGF-induced tyrosine phosphorylation of STAT3 was inhibited 
by the EGFR kinase inhibitor AG1478, indicating that EGF-induced STAT3 tyrosine 
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phosphorylation is EGFR-dependent (lane 5).  A similar result was observed with a 30 min 
EGF treatment with slightly lower tyrosine phosphorylation level of STAT3 compared to 10 
min EGF treatment, suggesting that EGF-mediated EGFR activation decreases after 30 
minutes (lane 6 and 7).  Interestingly, the antibody against activated EGFR detected a subtly 
shifted band in both 10 min and 30 min EGF-treated samples (lane 4 and 6, pointed by 
arrows) that was not detected with simultaneous AG1478 treatment (lane 5 and 7).  Although 
CTAR1 activated EGFR in the absence of serum, EGF treatment stimulated additional 
phosphorylation of EGFR to initiate signaling pathways downstream of EGFR, including the 
tyrosine phosphorylation of STAT3.  Overall, the data indicate that LMP1-CTAR1 can 
induce activation of EGFR, STAT3, and Bcl-3 expression independently of external growth 
factors.  Additionally, EGF treatment further stimulates the CTAR1-induced EGFR to induce 
tyrosine phosphorylation of STAT3. 
CTAR1 induces expression of EGFR ligand epiregulin.  To determine if CTAR1-
mediated serum-independent activation of EGFR reflects effects on EGFR ligands, real-time 
quantitative RT-PCR was performed to assess expression of TGFα, heparin-bound EGF (HB-
EGF), and epiregulin in serum-starved vector control and CTAR1-expressing C33A cells 
(Figure 2).  EGFR expression was analyzed as a positive control and expression levels were 
normalized to GAPDH.  The messenger RNA levels for TGFα and HB-EGF were not 
affected in CTAR1-expressing cells compared to vector control cells, while the mRNA 
expression of epiregulin was induced by 2.4-fold in CTAR1-expressing cells in the absence 
of serum compared to vector control cells.  This result suggests that epiregulin transcription 
is induced by LMP1-CTAR1, and this may contribute to CTAR1-mediated EGFR activation.  
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EGF treatment induces expression of STAT3 target genes in CTAR1 cells.  To 
determine if the STAT3 phosphorylation induced by EGF treatment increased expression of 
known STAT3 target genes, the RNA of EGF-treated CTAR1 cells was isolated and 
analyzed for expression of several known STAT3 targets, including SOCS3, Bcl-xL, Fos, 
Figure 1. LMP1-CTAR1 activates EGFR and STAT3 independent of serum, and  
CTAR1-induced EGFR further activates STAT3 in response to EGF treatment.  C33A  
cells stably transduced with pBabe or CTAR1 were maintained in DMEM with 10% FBS.   
CTAR1 cells were then serum-starved for 24 hours and treated with DMSO (lane 3), EGF for  
10min (lane 4), EGF/AG1478 for 10min (lane 5), EGF for 30min (lane 6), and EGF/AG1478  
for 30min (lane 7).  Whole cell protein lysates were prepared for western blot analysis.   
Activation of EGFR was detected by using antibody against Tyr1068 phosphorylation of  
EGFR.  The solid arrow points at CTAR1-activated EGFR.  And the dashed arrow points at  
the shifted EGFR after EGF treatment.  GAPDH was detected as a loading control and HA- 
specific antibody was used to detect expression of CTAR1. 
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CEBPD, and Cyclin D1, using real-time quantitative RT-PCR (Figure 3)  (48).  In the 
absence of serum CTAR1 induced EGFR expression 5.4-fold and treatment with EGF for 10 
min further increased EGFR mRNA expression to 7-fold.  However, after 30-min treatment 
of EGF this decreased to 6-fold.  The RNA levels of SOCS3 and Bcl-xL were not 
significantly changed after 10 or 30 min treatment of EGF.  Expression of cebpd went up by 
2.2-fold with 10 min EGF treatment but decreased down to 1.4-fold after 30 min treatment 
with EGF.  The expression of cyclin D1 increased by 2.7-fold after 10 min EGF treatment 
and stayed at 3-fold after 30 min treatment of EGF.  The mRNA of fos changed most 
dramatically with a 2-fold induction after 10 min EGF treatment and an increase of 
approximately 15.8-fold following 30 min treatment of EGF.  Statistical analysis revealed 
Figure 2. mRNA expression of EGFR ligands in CTAR1 cells.  Total RNA of pBabe  
control and CTAR1-expressing cells were extracted and subject to real-time quantitative RT- 
PCR using primers for EGFR ligands.  Results from RT-PCR were normalized to GAPDH  
and levels of EGFR ligands in pBabe control cells were set to 1-fold.  RT-PCR of each ligand  
was performed four times, with each one done in triplicate. 
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that the changes of Cyclin D1 and Fos were significant with p<0.05.  These data indicate that 
CTAR1-induced EGFR in response to EGF activates STAT3 to increase expression of 
specific targets of STAT3. 
PKCδ is responsible for CTAR1-induced serine phosphorylation of STAT3.  To 
identify the potential serine kinase responsible for CTAR1-mediated serine phosphorylation 
of STAT3, CTAR1-expressing C33A cells were treated with either DMSO or inhibitors of 
previously identified serine kinases of STAT3, including Rottlerin (PKCδ inhibitor), Gö6976  
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Figure 3. Expression level of STAT3 target genes in EGF-treated CTAR1-expressing  
C33A cells.  Total RNA was extracted from serum-starved CTAR1 cells treated with DMSO,  
EGF for 10min, or EGF for 30min and real-time quantitative RT-PCR was performed with  
primers against STAT3 target genes.   Results from RT-PCR were normalized to GAPDH  
and expressions of STAT3 targets in pBabe control cells were set to 1-fold.  Results are  
averages of at least three separate experiments, with each one performed in triplicate. 
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(PKCα/β inhibitor), U0126 (MEK/ERK inhibitor), and LY294002 (PI3kinase inhibitor) 
(Figure 4) (5).  As previously shown, CTAR1 (lane 2) induced EGFR expression, Bcl-3 
expression, and tyrosine / serine phosphorylation of STAT3 compared to parental C33A cells 
(lane 1).  Elevated levels of AKT and ERK phosphorylation were also detected in CTAR1-
expressing C33A cells.  The PKCδ inhibitor, Rottlerin, inhibited CTAR1-induced serine 
phosphorylation but not tyrosine phosphorylation of STAT3 at 5μM and more significantly at 
40μM (lane 3 and 4).  At 40μM, Rottlerin also reduced CTAR1-induced Bcl-3 protein 
expression.  Treatment with Rottlerin slightly decreased the effects of CTAR1 on EGFR.  In 
contrast, inhibition of MEK/ERK with U0126 or PI3kinase with LY294002 effectively 
decreased CTAR1-induced ERK phosphorylation and AKT phosphorylation, respectively, 
but did not block CTAR1-induced serine phosphorylation of STAT3 (lane 6 and 7).  
Treatment of CTAR1-expressing C33A cells with PKCα/β inhibitor, Gö6976, did not 
decrease serine phosphorylation of STAT3, indicating that CTAR1-induced serine 
phosphorylation of STAT3 was PKCδ-specific and independent of PKCα/β (lane 5).  These 
results indicate that PKCδ, but not PI3K, ERK, or PKCα/β, is responsible for LMP1-CTAR1-
induced serine phosphorylation of STAT3.  Importantly, inhibition of PKCδ activity also 
blocked phosphorylation of ERK (lane 3 and 4) but did not affect activation of 
PI3kinase/Akt.  This suggests that in addition to serine phosphorylation of STAT3, PKCδ is 
also responsible for the CTAR1-induced and endogenous ERK phosphorylation in C33A 
cells. 
PKCδ is important for CTAR1-mediated transformation of Rat-1 cells.  To test 
the requirement for PKCδ in LMP1-mediated transformation, the effect of its inhibition was 
assessed using a focus formation assay in Rat-1 fibroblast cells (Figure 5A).  Subconfluent 
162 
 
                     
+
EGFR
Ser-P-STAT3
Tyr-P-STAT3
Bcl-3
GAPDH
P-AKT(S473)
P-ERK
–
C33A
+ + – – – – –
– – 5uM 40uM – – –
– – – – 5nM – –
– – – – – 10uM –
– – – – – – 25uM
CTAR1
DMSO
Rottlerin
Gö6976
U0126
LY294002
1 2 3 4 5 6 7
+ + + + +
 
 
 
 
 
Rat-1 cells were transduced with LMP1-CTAR1 (1-220)-containing retrovirus at three 
different dilutions (10-1, 10-2, and 10-3).  CTAR1 induced many foci at the 10-1 dilution which 
Figure 4. LMP1-induced serine phosphorylation of STAT3 is PKCδ-dependent.  C33A  
cells stably transduced with pBabe or CTAR1 were maintained in DMEM with 10% FBS.   
The medium were replaced with serum-free medium for 24 hours and both cells were  
treated with DMSO for 5 hours (lane 1 and 2).  CTAR1 cells were also treated with the  
PKCδ inhibitor (Rottlerin, lane 3 and 4), PKCα/β inhibitor (Gö6976, lane 5), MEK/ERK  
inhibitor (U0126, lane 6), and PI3K inhibitor (LY294002, lane 7) for 5 hours.  Whole cell  
protein lysates were prepared for western blot analysis.  GAPDH was detected as a loading  
control. 
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was decreased with the 10-2 and 10-3 retrovirus dilutions.  Treatment with 1μM Rottlerin 
blocked focus formation at all three dilutions.  Western blot analysis indicated that ERK 
phosphorylation was significantly decreased by Rottlerin treatment in Rat-1 cells transduced 
with 10-1 or 10-2 dilutions of retrovirus that also had the most significant reduction of focus 
formation (Figure 5B).  Immunoblotting with total-ERK antibody indicated that the total  
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Figure 5. PKCδ inhibitor, Rottlerin, inhibited CTAR1-induced focus formation.  A)  
Rat-1 cells were transduced with pBabe and CTAR1(1-220) at three different dilutions,  
maintained for 10 days, stained with crystal violet, and observed for focus formation.  B)  
Whole cell protein lysates were prepared from a duplicate focus formation experiment of A).   
Western blot analysis was performed using antibodies against total ERK and phosphorylated  
ERK.  GAPDH was detected as a loading control. 
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level of ERK was not affected and GAPDH expression was assessed as an internal control.  
This result indicates that PKCδ is required for LMP1-mediated transformation of Rat-1 cells.  
As ERK activation has been previously shown to be required for LMP1-mediated Rat-1 
transformation, the block of transformation by rottlerin inhibition of PKCδ confirms that 
PKCδ mediates the activation of ERK by LMP1-CTAR1. 
LMP1-CTAR1 induces Tyrosine-311 phosphorylation of PKCδ.  PKCs mature 
and are activated through a series of phosphorylation steps(14, 39).  To analyze the activation 
of PKCδ by CTAR1 in C33A cells, whole cell lysates of CTAR1-expressing C33A cells 
were assessed by western blotting using antibodies against total PKCδ and two specific 
phosphorylations that have been suggested to be important for PKCδ activity, Threonine 505  
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Figure 6. Tyrosine-311 phosphorylation of PKCδ is elevated in CTAR1 C33A cells.   
C33A cells stably expressing pBabe or CTAR1 were assayed for total level of PKCδ, Thr505 
phosphorylation of PKCδ, and Tyr311 phosphorylation of PKCδ by western blot analysis.  
GAPDH expression was detected as a loading control. 
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and Tyrosine 311 (24, 27, 51, 52).  The total protein level of PKCδ was similar in both 
pBabe- and CTAR1-expressing C33A cells (Figure 6).  Overexpression of CTAR1 induced 
Tyr-311 phosphorylation of PKCδ but reduced Thr-505 phosphorylation of PKCδ.  These 
data suggest that CTAR1-mediated PKCδ activity is not dependent on the phosphorylation at 
Thr-505 but that Tyr-311 phosphorylation of PKCδ might contribute to its activity in 
CTAR1-expressing C33A cells. 
 
DISCUSSION 
These data presented in this report reveal that LMP1-CTAR1 can activate both EGFR 
and STAT3 independently of serum growth factors, and that EGFR can be further activated 
by EGF treatment to induce tyrosine phosphorylation of STAT3 and expression of STAT3 
targets.  More importantly, these studies also identified PKCδ as the likely serine kinase of 
STAT3, as well as the upstream effector of ERK activation mediated by LMP1-CTAR1.  The 
ability of PKCδ inhibitor Rottlerin to inhibit CTAR1-induced transformation points to the 
importance of this kinase in LMP1-mediated oncogenesis. 
One possible cause for this serum-independent activation of EGFR is CTAR1-
mediated induction of EGFR ligands.  It has been shown that LMP1 transactivates TGFα and 
enhances TGFα secretion in T cells (26).  However, in CTAR1-expressing C33A cells, 
expression of TGFα was not altered, yet, transcription of another EGFR ligand, epiregulin, 
was increased.  Interestingly, in an LMP1 transgenic mouse model with epidermal 
hyperplasia, hyperphosphorylation of EGFR occurs concomitantly with induced TGFα, HB-
EGF, and epiregulin expression, suggesting that LMP1 can activate EGFR activation through 
induction of EGFR ligands, such as epiregulin (3).  Taken together, the serum-independent 
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activation of EGFR observed in this study could provide a mechanism for the increased 
growth characteristics of LMP1-expressing epithelial cells in serum-free environment (34). 
These data also indicate that CTAR1-induced EGFR responded to EGF treatment 
which greatly increased the tyrosine phosphorylation of STAT3.  This phosphorylation was 
blocked by treatment with the EGFR inhibitor AG1478, indicating this was an EGFR-
specific effect.  It is well established that EGFR can activate the JAK/STAT pathway and can 
also physically interact and phosphorylate STAT3 directly.  This activation is important for 
inhibition of apoptosis, cell growth, and cell proliferation in cancer cells of epithelial origins 
(19, 43, 44).  EGFR expression and STAT3 activation are also elevated in NPC, suggesting 
that LMP1 contributes to NPC development through its effects on EGFR, STAT3 activation, 
and regulation of STAT3 target genes (2).   In response to EGF, CTAR1 cells had greatly 
increased mRNA for specific STAT3 target genes, including cyclin D1 and fos ,which have 
been shown to be induced by LMP1 (Figure 3) (49, 54).  In breast carcinoma, the EGFR 
signaling pathway induces epithelial-mesenchymal transition (EMT) of cancer cells through 
STAT3-mediated TWIST gene expression, and subsequently E-cadherin downregulation 
(28).  LMP1 has also been shown to induce TWIST expression and EMT in NPC cells (16).  
These findings suggest that by inducing EGFR expression, LMP1 mediates the EGFR-
STAT3 signaling pathway to regulate cellular transcriptional and biologic properties.   
Previous studies have identified several phosphotyrosine residues in the C-terminal 
tail of EGFR to be important for recruitment of STAT3 to EGFR and activation of STAT3, 
including Tyr992, Tyr1045, Tyr1086, and Tyr1068 (47).   It is possible that CTAR1-
mediated serum-independent activation of EGFR is responsible for the low levels of tyrosine 
phosphorylation of STAT3 observed in serum-starved CTAR1 cells (Figure 1).  Additional 
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phosphorylation induced by EGF treatment likely enhances the interaction between STAT3 
and EGFR, resulting in increased STAT3 phosphorylation/activation (Figure 1). 
CTAR1 also induced serum-independent serine phosphorylation of STAT3, which 
was not changed by treatment with EGF or its inhibitor, AG1478, suggesting that the 
CTAR1-induced serine phosphorylation of STAT3 was not dependent on EGFR signaling 
(lane 4-7 of Figure 1).  STAT3 serine phophorylation can be induced by several serine-
threonine kinases including ERK, PI3K, and PKCδ (5).  However, specific inhibition of these 
serine kinases indicated that only the PKCδ-inhibitor Rottlerin reduced serine 
phosphorylation of STAT3 (Figure 4).  This result demonstrates that PKCδ, but not PKCα/β, 
ERK, or PI3K, is responsible for CTAR1-induced serine phosphorylation of STAT3.  LMP1 
has not been previously shown to activate the PKCδ-dependent signaling pathways, although 
it does regulate annexin 2 and ezrin through PKCα/β (9, 30).  Interestingly, PKCδ, which is 
known to activate the MAPK pathway through different mechanisms, also blocked both 
CTAR1-induced and endogenous ERK phosphorylation (18).  These findings suggest that 
PKCδ may function as a master regulator for both LMP1-mediated STAT3 and ERK 
activation. 
Inhibition of  LMP1-CTAR1-mediated activation of ERK blocked rodent fibroblast 
transformation (32, 42).  The inhibition of focus formation and ERK phosphorylation by the 
PKCδ inhibitor in Rat-1 cells indicates that PKCδ is required for LMP1-mediated 
transformation, potentially by regulating ERK activation (Figure 5).  PKCδ-mediated serine 
phosphorylation of STAT3 has been shown to be important for keratinocyte proliferation, 
and LMP1 activation of STAT3 is required for the enhanced growth properties of LMP1 
transgenic lymphocytes (12, 45).  However, the role for PKCδ-mediated serine 
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phosphorylation of STAT3 in LMP1-mediated transformation and NPC development has not 
been determined. 
Phosphorylation patterns of PKCδ in response to different stimuli are complex (18, 
39).  Phosphorylation at the activation-loop site is the important first step for maturation and 
activation of PKCs (14).  Based on sequence homology, phosphorylation of Thr505 at 
PKCδ’s activation-loop is thought to be important for its activity (27, 39).  However, 
increased Thr505 phosphorylation of PKCδ in CTAR1-expressing C33A cells compared to 
vector control cells was not detected (Figure 5).  It has been shown that bacteria-generated 
PKCδ retains catalytic activity despite lack of phosphorylation at Thr505 (51).  Instead, 
increased levels of Tyr311 phosphorylation of PKCδ was detected in CTAR1-expressing 
C33A cells.  A study using mass spectrometry showed that Tyr311 phosphorylation is critical 
for increased activity of PKCδ in response to H2O2 (24).  Interestingly, LMP1 has been 
shown to induce production of H2O2 in EBV-negative nasopharyngeal epithelial cell line 
(55).  This suggests that LMP1, through CTAR1, may activate PKCδ through inducing 
production of H2O2.  PKCδ can be regulated by PI3K through PDK1 (27).  However in these 
studies, PI3K-specific inhibitor did not reduce CTAR1-induced serine phosphorylation fo 
STAT3 indicating that PI3K-PDK1 signaling is not responsible for PKCδ-mediated 
phosphorylation of STAT3 in CTAR1-expressing cells (Figure 3).  A recent study also 
suggested that EGFR can mediate tyrosine phosphorylation of PKCδ in H2O2-stimulated 
cells (36).  It will be interesting to determine the exact phosphorylation profile of PKCδ and 
identify potential additional kinases that contribute to PKCδ activation in LMP1/CTAR1-
expressing cells. 
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In summary, this study reveals that LMP1-CTAR1 mediates STAT3 signaling 
pathways through EGFR and PKCδ.  The CTAR1-activated EGFR responds to EGF 
stimulation to increase tyrosine phosphorylation of STAT3 and regulate expression of 
STAT3 target genes.  CTAR1 additionally induces serine phosphorylation of STAT3 and 
ERK activation through PKCδ.  These combined effects of LMP1 on EGFR and STAT3 
likely increase the transcription of additional cellular genes.  The further study of the effect 
of LMP1 on these pathways will enhance our understanding of the mechanisms through 
which EBV contributes to oncogenesis. 
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Considering that EBV infects more than 90% of the world’s adult population, the 
human immune system is really underappreciated for doing an amazing job in keeping this 
virus in check.  The majority of the primary and persistent EBV infections are asymptomatic 
for a lifetime without causing health problems.  The most common concern for EBV 
infection is the development of infectious mononucleosis (IM) when the primary infection 
occurs in adolescence or early adulthood.  But IM is normally a self-limited illness and the 
mild symptoms caused by IM usually recede after several weeks. 
However, due to the ubiquitous nature of EBV infection, the number of serious 
diseases caused by EBV simply cannot be ignored.  Two major EBV-associated cancers, 
nasopharyngeal carcinoma and Hodgkin disease, although have relatively low incidence-rate 
in the US, still have 11,000 and 7300 cases per year in the US, respectively (53).  Moreover, 
EBV infection is also associated with some forms of approximately 60,000 new cases of non-
Hodgkin lymphoma (NHL) in US each year, including Burkitt’s lymphoma.  Burkitt’s 
lymphoma is especially prevalent in persons younger than 20-year-old, where approximately 
40% of NHL cases are Burkitt’s lymphoma in western countries (67).  In some cases EBV-
associated malignancies also exhibit specific patterns of geographical distribution, potentially 
due to environmental, genetic, and other factors that may have predisposing effects on EBV-
associated diseases.  For example, EBV-associate endemic Burkitt’s lymphoma has an 
incidence rate at 10-15 cases per 100,000 human population in New Guinea and equatorial 
regions of Africa, and accounts for 20-50% of all pediatric malignancies in certain areas (45, 
64).  In Chinese Cantonese males who live in Hong Kong or Guangzhou, the incidence rates 
can climb up to over 100 cases per 100,000 population per year (14).  These facts make EBV 
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a significant threat for human health and further understanding of EBV-mediated 
tumorigenesis is necessary.  
EBV-associated malignancies mainly occur in two cell types, B cells and epithelial 
cells.  Persistent infection of EBV in these two cell types is characterized based on three 
different latency types of gene expression, latency type I, II, and III.  EBV’s major 
oncoprotein, latent membrane protein 1 (LMP1), is expressed in type II and type III latency 
and is consistently found in several EBV-associated cancers.  Many studies have focused on 
LMP1 as it is essential for EBV-mediated B-cell transformation and it alone can transform 
rodent fibroblasts (22, 63).  Although LMP1’s functions have been mainly mapped to two 
signaling domains CTAR1 and CTAR2, it has been shown that CTAR1 is required for 
LMP1-mediated transformation while CTAR2 is dispensable (34, 35).  Therefore, most of 
the studies in this dissertation have focused on CTAR1’s contribution to LMP1-mediated 
gene regulation and transformation. 
It has been shown that LMP1, through CTAR1, upregulates EGFR expression in 
epithelial cells and EGFR is induced in most EBV-associated NPCs (38, 52, 69).  This 
transcriptional upregulation has been found to be mediated by a novel NF-κB complex 
comprised with p50 homodimer and Bcl-3 (58, 59).  In chapter 2, we revealed that LMP1-
CTAR1 also induces the expression of Bcl-3 at the transcriptional level and this upregulation 
is mediated by CTAR1-activated STAT3.  Inhibition of CTAR1-induced STAT3 
phosphorylation results in the downregulation of Bcl-3 and EGFR, indicating that CTAR1 
activates STAT3 to directly and indirectly affect cellular gene expressions in epithelial cells.  
It has been shown that LMP1 activates STAT3 to initiate an autoregulatory loop in which 
activated STAT3 regulates EBNA1 and LMP1 expression (5, 6).  Moreover, STAT3 has also 
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been shown to be responsible for LMP1-induced expression of MUC1 (25).  This finding 
suggests that by activating STAT3 pathway, LMP1 is able to have a global effect on 
expression of both viral and cellular genes.  The detection of induced STAT3 activation in 
NPC specimens and LMP1-transgenic mice suggests that activation of STAT3 is an 
important signaling event LMP1 manipulates to control cell transformation (2, 51).  A recent 
study further supports this implication by showing that STAT3 is directly involved with cell 
proliferation and invasiveness of EBV-infected NPC cell lines (33).  With improved 
technologies, it is much easier to identify targets of transcriptional factors (TFs) at the 
genome-wide level (10).  Chromatin-immunoprecipitation-sequencing (ChIP-seq) and ChIP-
on-chip analyses have been applied widely to study transcriptional regulatory networks.  
With its importance in regulating various cell functions, STAT3 has been subject to ChIP-seq 
analysis in embryonic stem (ES) cells and comprehensive mapping of STAT3-targeted genes 
is being explored (7, 15).  This accumulating information may be useful to identify potential 
targets of LMP1-activated STAT3 and their functions in LMP1-mediated transformation.  
Conversely, it may be a good idea to apply these techniques to identify potential targets of 
STAT3, or even other LMP1-activated TFs, in the expression of LMP1.  It may dramatically 
increase our understanding of LMP1’s roles in transcriptional regulation. 
At roughly the same time of our study, another report also confirmed the induction of 
Bcl-3 in LMP1-expressing cells (43).  Despite the fact that this study suggested that LMP1 
induces Bcl-3 through CTAR2-mediated NF-κB pathway, it is apparent that protooncogene 
Bcl-3 is downstream target of LMP1 and its induction may contribute to LMP1-mediated 
transformation.  Bcl-3 has been shown to complexes with p52- or p50-homodimers to 
transactivate gene expression, including cyclin D1 (48, 66).  This provides an additional 
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mechanism for LMP1-induced cyclin D1, which was suggested to be regulated by c-
Jun/JunB (54, 55).  Another potential function of Bcl-3 is to suppress p53 activity by 
inducing the expression of Hdm2 (21).  LMP1 also regulates p53 activity through the 
induction of A20, indicating that p53 is an important target of LMP1-mediated oncogenesis 
(12). 
As mentioned in chapter 2, Bcl-3 has been reported to be phosphorylated by GSK3 
and it leads to proteasome-mediated degradation of Bcl-3 (62).  LMP1 has also been shown 
to inactivate GSK3 potentially through activation of Akt (34).  It is therefore possible that 
LMP1 could upregulate Bcl-3 post-transcriptionally by inactivating its negative regulator 
GSK3.  Our preliminary data showed that although the treatment of GSK3 inhibitors further 
increased Bcl-3 protein level in cells expressing CTAR1, inhibition of GSK3 alone was not 
sufficient to induce Bcl-3 expression (data not shown).  Moreover, the presence of CTAR1 
did not increase Bcl-3’s stability upon treatment with protein synthesis inhibitors (data not 
shown).  This indicates that LMP1-CTAR1 increases Bcl-3 expression solely through 
transcriptional upregulation.  Interestingly, a recent study showed that GSK3 inhibitors 
blocked STAT3 DNA binding activity and the expression of STAT3-induced Bcl-3, 
suggesting an autoregulatory mechanism for LMP1-regulated Bcl-3 expression (1).  Nuclear 
translocation of Bcl-3 has been shown to be regulated by K63-linked ubiquitination, which 
can be blocked by the deubiquitinase  CYLD (36).  LMP1 has been shown to induce K63-
linked ubiquitination, albeit through CTAR2-associated RIP (18).  Whether CTAR1 induces 
nuclear translocation of Bcl-3 observed in our study through a similar mechanism remains to 
be determined. 
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In chapter 3, we investigated the roles of NF-κB pathways in LMP1-CTAR1-
mediated EGFR upregulation using mouse embryonic fibroblasts (MEFs).  It has been shown 
previously that LMP1 induces EGFR expression through TRAF-binding motifs and 
canonical NF-κB pathways may play a role in the event (38).  Surprisingly, using MEFs 
defective for different NF-κB effectors, we found that CTAR1 induces EGFR expression in 
MEF cells and the induction is completely abrogated in the absence of functional NIK.  
Induction of EGFR in IKKα-/-, IKKβ-/-, and IKKγ-/- cells suggests that LMP1-mediated 
EGFR induction is not dependent on either canonical or noncanonical NF-κB pathway.  A 
previous study suggested that LMP1-CTAR1 activates an atypical IKKβ-dependent/IKKγ-
independent NF-κB pathway in addition to IKKβ/IKKγ-dependent canonical and NIK/IKKα-
dependent noncanonical pathways (32).  This argues that the function of individual IKKs 
may be critical for specific LMP1-mediated gene regulation.  Our study revealed that LMP1 
induces EGFR expression through another “atypical” NF-κB signaling event which is NIK-
dependent.  The canonical and noncanonical NF-κB pathways may also contribute to LMP1-
mediated EGFR upregulation, however, as IκBα and dominant-negative constructs of 
IKKα/IKKβ decreased EGFR expression and a relatively mild induction of EGFR was 
observed in IKKα-/- and IKKβ-/- cells (38, 59).  Moreover, the extent of EGFR induction 
mediated by LMP1 may also be affected by the basal level of EGFR detected in each MEF 
mutant cell.  It will be interesting to see if functions of any of these NF-κB effectors are 
affected endogenously in C33A cells, the cell line with extremely low basal level of EGFR 
for studies of LMP1-mediated EGFR upregulation. 
It is not yet clear how NIK affects CTAR1-mediated EGFR upregulation.  One 
possibility is that NIK may contribute to EGFR induction by activating STAT3 through 
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phosphorylation as reported recently (41).  This hypothesis is consistent with the reduction of 
STAT3 serine phosphorylation in CTAR1-expressing NIK-defective MEFs and CTAR1-
expressing C33A cells transfected with NIK (K-A) construct.  However, overexpression of 
NIK failed to increase serine phosphorylation of STAT3 in epithelial cell lines and NIK-
defective MEFs.  This indicates that although NIK is critical for LMP1-mediated EGFR 
upregulation, other factors associated with NIK may be also required.  Furthermore, it will be 
interesting to see if STAT3-regulated Bcl-3 expression, as described in chapter 2, plays a role 
in CTAR1-mediated EGFR induction in MEF cells.  The result that NIK (K-A), but not 
DNNIK and DNNIKaly, constructs exhibited dominant-negative effects on CTAR1-induced 
EGFR was consistent with the lack of CTAR1-mediated EGFR upregulation in NIKaly/aly 
MEF cells.  It also indicates that association with other proteins may be important for NIK’s 
activity to mediate EGFR induction, since aly-mutation is known to abrogate NIK’s 
interaction with its binding partners, including IKKα and TRAFs (11).  Additionally, we also 
showed that CTAR1 was able to induce EGFR expression in TRAF6-defective, but not 
TRAF2- or TRAF3-defective cells.  It will be interesting to see if the interactions between 
NIK and TRAF2 or TRAF3 are important for LMP1-mediated EGFR upregulation.  It has 
been shown that TRAF3 can function as a negative regulator of NIK by inducing NIK 
ubiquitination and degradation.  Therefore, LMP1-CTAR1 could potentially activate the 
NIK-mediated signaling pathway by interacting with and sequestering TRAF3, which would 
indicate that the lack of CTAR1-induced EGFR in TRAF3-defective cells is due to separate 
mechanisms. 
The NF-κB member p50 forms a transactivating complex with Bcl-3 and this 
complex is responsible for LMP1-mediated EGFR upregulation (58, 59).  The activation of 
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p50 is also found in LMP1-expressing cells or NPC (27, 46, 58).  In chapter 3, we showed 
that CTAR1-induced p50 activation is consistent among most MEF mutant cells that have 
induced EGFR, including IKKβ-, IKKγ-, and TRAF6-defective MEFs.  CTAR1 failed to 
activate p50 in TRAF2-defective cells, indicating that TRAF2 may contribute to LMP1-
mediated EGFR upregulation through regulating p50 activation.  However, in NIK- or 
TRAF3-defective MEFs where CTAR1-induced EGFR expressions were abrogated, 
activation of p50 was still detected.  This suggests that although the p50 homodimer can 
transcriptionally induce EGFR, its importance varies among mutant MEFs we used in this 
study.  It has been shown that the presence or absence of specific TRAFs can tilt the 
importance to other TRAFs in LMP1-mediated signaling pathways (8, 31).  The increased 
p50 activation in TRAF3-defective cells could reflect the role of TRAF2 in mediating p50 
activation, while also indicates that there are TRAF3-dependent pathways regulating EGFR 
induction.  We also showed that CTAR1-induced p50 activation is mediated by a 
proteasome-dependent pathway (26).  It will be interesting to see if LMP1 activates p50 via 
other possible pathways, such as importin-dependent protein transportation (9). 
In addition to p50-homodimer/Bcl-3 regulation, EGFR can be transcriptionally 
regulated by several other mechanisms.  For example, the p53 homologue p63 represses the 
transcriptional expression of EGFR (44).  EGFR expression is also inhibited by microRNA-7 
(23, 65).  Given LMP1’s ability to regulate multiple signaling pathways and its newly-found 
roles in regulating miRNA expression, it is possible that LMP1 also regulates these 
mechanisms to affect EGFR level or cellular gene expression in general (13, 56). 
EGFR upregulation has been well documented in NPC and inhibition of EGFR 
activity has detrimental effects on cell growth of NPC cells (47, 68, 70).  In addition to 
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EGFR upregulation, we revealed in chapter 4 that LMP1-CTAR1 also activates EGFR both 
in the absence of serum and upon treatment of EGF.  CTAR1-activated EGFR may be 
responsible for the regulation of certain LMP1-responsive cellular genes both intrinsically 
and in response to external stimulation, such as EGF.  It is not yet clear how LMP1, through 
CTAR1, activates EGFR in the absence of growth factors.  However, the induction of EGFR 
ligand epiregulin in CTAR1-expressing C33A cells may contribute.  Epiregulin expression 
has also been found to be increased in LMP1 transgenic mice, supporting this hypothesis (4).  
Several recent studies have shed some light on a new ErbB-activating mechanism 
involved with exosome-mediated shedding of ErbBs, including EGFR and HER2 (29, 49, 
50).  Full-length and proteolytically-processed EGFRs can be secreted through small 
membrane vesicles called exosomes in human keratinocyte cell line.  These secreted EGFRs 
retain ability to bind to ligands and potentially retain its tyrosine kinase activity.  
Additionally, EGFR shedding is correlated with a highly malignant cell phenotype, 
indicating that this phenomenon might contribute to EGFR-induced cell proliferation and 
invasion.  Interestingly, LMP1 has recently been shown to not only present in exosomes of 
NPC cells, but also promote exosome release of a potent growth factor, FGF-2 (3, 24, 37).  
Exosome-mediated secretion of LMP1 has recently been suggested to be responsible for the 
detection of LMP1 in the sera and saliva of a majority of NPC patients (17).  One EGFR 
ligand, HB-EGF, has been shown to undergo PKCδ-induced ectodomain shedding (19, 61).  
In this study we showed that LMP1 can induce downstream signaling pathways through 
PKCδ.  Metalloproteinases are important for the process of shedding membrane-anchor 
proteins, and LMP1 is known to induce expression of several MMPs, including MMP1, 2, 3, 
and 9 (16, 19, 28, 40, 42, 57, 61).  These findings suggest that LMP1 potentially activates 
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EGFR in a serum-independent manner by regulating protein trafficking pathways involving 
exosome productions.  Studies designed to test this hypothesis are currently under 
development. 
Another important finding in chapter 4 was the identification of PKCδ as the 
upstream effector of LMP1-CTAR1-mediated activations of STAT3 and ERK, and show that 
PKCδ activity is required for CTAR1-mediated transformation in rodent fibroblasts.  These 
findings have brought us one step closer to determine how LMP1 induces two of its 
downstream pathways, STAT3 and MAPKK/ERK activations.  Although we identified 
increased phosphorylation of Tyr311 of PKCδ to be one marker of PKCδ activation, due to 
the complex nature of PKCδ’s phosphorylation and regulation, it remains to be determined 
how LMP1 regulates PKCδ activity in epithelial cells (20).  Notably, EGFR has been shown 
to be able to regulate PKCδ through specific phosphorylations (39).  Therefore, it will be 
interesting to see if it is an interplay between LMP1-regulated EGFR and PKCδ activation.  
A couple of recent studies showed that PKCδ activates p65 to induce expression of 
downstream targets in response to TNFα or phorbol 12-myristate 13-acetate (PMA, also 
called TPA) (30, 60).  Considering that LMP1 is a potent activator of NF-κB signaling and 
the common application of TPA in studying EBV lytic replication from latently-infected 
cells, it will be interesting to investigate PKCδ’s role in NF-κB activity in both lytic and 
latent infection of EBV. 
In summary, these studies have helped us further understand different signaling 
pathways which LMP1, especially through CTAR1, utilizes to control expression of cellular 
genes that may contribute to LMP1- and EBV-mediated tumorigenesis (Figure 1).  Using 
LMP1-mediated EGFR upregulation as the model, we found that LMP1-CTAR1 activates 
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STAT3 to induce expression of the critical member of EGFR’s transcriptional regulator, Bcl-
3.  CTAR1 activates STAT3 through PKCδ and potentially NIK, which is also required for 
CTAR1-mediated EGFR induction.  STAT3 can be further activated through CTAR1-
activated EGFR in response to EGF to induce downstream target genes, including Fos and 
cyclin D1.  PKCδ was also found to be an upstream regulator of ERK activation and was 
required for CTAR1-mediated transformation of rodent fibroblasts.  Moreover, CTAR1-
mediated EGFR upregulation is dependent on TRAF2 and TRAF3 but not TRAF6, and 
TRAF2 may contribute to EGFR induction by regulating p50 activation.   
The further understanding of the complexity of LMP1’s effects on signaling pathways 
will help clarify the contribution of LMP1 to EBV pathogenesis.  Since I started graduate 
study five years ago, significant progress has been made in the last five years in the field of 
EBV research.  The first viral miRNA was identified in EBV, followed by approximately 40 
publications to date discussing the relationship between EBV and miRNA (both viral and 
cellular).  More positive correlations were established between EBV infection and 
autoimmune disease such as MS.  Promising results came out of phase I and phase II trials of 
EBV vaccines.  A connection was made between the invasiveness of EBV-associated 
malignancies and EBV’s ability to regulate the composition of cellular junction proteins.  
And multiple signaling pathways have been identified during different stages of EBV 
infection.  It will be an honor to consider this dissertation has made a contribution, however 
small, to our knowledge of EBV pathogenesis and the never-ending fight to stop diseases 
associated with EBV. 
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Figure 1. CTAR1-mediated signaling pathways for EGFR upregulation.  LMP1-CTAR1 
engages multiple signaling pathways to upregulate EGFR expression.  CTAR1 induces 
expression of Bcl-3 through activation of STAT3, which is mediated by PKCδ and possibly NIK.  
NIK is required for CTAR1-mediated EGFR induction, which is not  dependent on either 
canonical or noncanonical NF-κB pathways.  In addition to STAT3 activation, CTAR1 may also 
mediate ERK activation through PKCδ.  CTAR1 induces p50 activation in a proteasome-
independent but TRAF2-dependent manner.  CTAR1-activated EGFR can phosphorylate STAT3 
and induce expressions of downstream targets of  STAT3 in response to EGF.  
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